CA2411109A1 - Container for medicament powder - Google Patents
Container for medicament powder Download PDFInfo
- Publication number
- CA2411109A1 CA2411109A1 CA002411109A CA2411109A CA2411109A1 CA 2411109 A1 CA2411109 A1 CA 2411109A1 CA 002411109 A CA002411109 A CA 002411109A CA 2411109 A CA2411109 A CA 2411109A CA 2411109 A1 CA2411109 A1 CA 2411109A1
- Authority
- CA
- Canada
- Prior art keywords
- medicament
- container
- desiccant
- package
- container according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0053—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal
- A61M15/0055—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal the used dosages being coiled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/062—Desiccants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/06—Packaging for specific medical equipment
Abstract
There is provided a container for a medicament powder formed from a material comprising a desiccant. In one embodiment the container is a medicament dispenser comprising a body defining a reservoir for medicament in powder form, and an outlet in communication with said reservoir. In another embodiment the container is a medicament dispenser comprising a body defining a chamber for receipt of a medicament carrier, and an outlet in communication with said chamber. Methods of controlling moisture flow are also described.
Description
CONTAINER FOR MEDICAMENT POWDER
Technical Field The present invention relates to containers and dispensers for medicament powders.
In particular, the invention relates to dry powder inhalation dispensers and components thereof which substantially alleviate or reduce moisture build-up therein.
The invention also relates to a method for reducing moisture ingress inside a dry io powder inhaler.
Background to the Invention Is Medicaments for treating respiratory disorders are frequently administered as dry powder formulations through the mouth and nose. Dry powder medicament dispensers, such as inhalers, are used in the administration of these drugs, inhalation by the patient resulting in uptake of a specified dosage of medicament through the nose or mouth. The drug may be stored as a dry powder within a 2o reservoir in the body of the inhaler, a metering chamber being utilised to administer a specified dose of medicament. Alternatively, more sophisticated medicament dispensers employ medicament carriers, such as individual capsules or blister packs/strips containing defined doses of powdered drug.
2s Patients often rely on medication delivered by dry powder inhalers for rapid treatment of respiratory disorders that are debilitating and in some cases life threatening. It is, therefore, essential that the prescribed dose of drug is delivered accurately and consistently to meet the patient's needs and comply with the requirements of regulatory authorities.
A problem which can occur in the storage and product lifetime of an inhaler is ingress of moisture into the medicament powder. A build-up of moisture can prevent the administration of an effective dose of medicament by causing an increase in particle size and/or adherence of hygroscopic particles to the walls of the carrier or s device, thereby leading to reduced uptake via inhalation by the patient. fn extreme cases, depending upon the chemical nature of the medicament, moisture build-up may lead to degradation of the drug.
Another problem can be microbial contamination, which is often assisted by the to undesirable presence of excess moisture.
The Applicants have found that the inclusion of a desiccant in the body of the inhaler or the walls of the medicament carrier can significantly improve the aforementioned problems. Furthermore, storage of the inhaler or medicament carrier within a sealed Is package incorporating a desiccant, can markedly reduce moisture ingress.
The Applicants has also found that the aforementioned problems can be ameliorated by controlling the ingress of moisture to, or egress of moisture from, the medicament container. Control may be achieved by either suitable choice of container materials 20 or by enclosure of the container or a dispenser including the container in a suitable package. The control need not absolutely prevent moisture transfer. Indeed, the Applicants have found that under certain conditions a limited degree of moisture transfer can be desirable.
2s WO 99/32180 teaches the inclusion of moisture permeable chambers containing desiccants within a blister pack. US patent 5,740,793 discloses the inclusion of a desiccant cartridge within an inhaler or the medicament carrier cassette. US
patent 5,394,868 describes a chamber within a powder inhaler for holding a desiccating substance. The use of desiccant filters within medicament dispensers is described 3o in US patents 5,687,746 and 5,775,320, and PCT patent application no. WO
01348.
Summary ofi Invention s According to the present invention, there is provided a container for a medicament powder formed from a material comprising a desiccant.
In one aspect, the container is suitable for containing a measured dose of medicament. Packs in blister pack form for the containment of a unit dose Io medicaments are envisaged, as are packs containing multiple unit dose blisters arranged sequentially or otherwise, such as in series form. A particular multi-unit dose arrangement comprises an elongate strip having multiple blisters arranged in series thereon.
Is In another aspect, the container is a reservoir for dry powder medicament.
Metering means are provided to enable metering of dose from the reservoir and transport of that dose to a delivery position.
In one aspect, the container is a medicament dispenser comprising a body defining a 2o reservoir for medicament in powder form, and an outlet in communication with said reservoir for release of the medicament. In one aspect, the device is an inhaler and the outlet is one through which a user can inhale.
In another aspect, the container is in the form of a reloadable cartridge comprising a 2s medicament pack (e.g. in multi-unit dose blister form or reservoir form).
The cartridge is shaped and sized for receipt by a medicament delivery device (e.g. an inhaler device).
In another aspect, the container is a medicament dispenser comprising a body 3o defining a chamber for receipt of a medicament carrier, and an outlet in communication with said chamber for release of the medicament. In one aspect, the device is an inhaler and the outlet is one through which the user can inhale.
In yet another aspect, the body consists of the material comprising the desiccant.
s In one aspect, the body comprises the material comprising the desiccant.
In another aspect, the material comprising the desiccant coats the body e.g.
part or whole of the inside of the body.
io In yet another aspect, the material comprising the desiccant is impregnated throughout the body.
In one aspect, the material comprising the desiccant lines the body (e.g. the interior Is of the body which contacts the medicament powder in use).
Optionally the desiccant comprising material may be located around a seal for sealing the reservoir or medicament carrier optionally the seal (e.g. in the form of a sealing ring) may itself comprise or consist of a desiccant.
In another aspect, the container is a medicament carrier.
In yet another aspect, the medicament carrier is a capsule comprising a wall enclosing the medicament.
In one aspect, the medicament carrier is a blister pack comprising a base sheet and a lid.
In another aspect, the medicament carrier comprises a material comprising a 3o desiccant.
In yet another aspect, the material comprising the desiccant coats the wall, or the base sheet, or the lid of the medicament carrier.
fn one aspect, the material comprising the desiccant impregnates the wall, or base s sheet, or lid of the medicament carrier.
In another aspect, the material comprising the desiccant lines the wall, or base sheet, or lid of the medicament carrier.
to In another aspect, the material comprising the desiccant is moulded into the wall, or base sheet, or lid of the medicament carrier.
In yet another aspect, a well containing desiccant surrounds individual pockets in the blister packs.
is In one aspect, the blister pack comprises a laminate comprising a desiccant.
Suitably, the laminate comprises material selected from the group consisting of metal foil, organic polymeric material and paper. Suitable metal foils include aluminium or tin foil having a thickness of from 5 to 100p,m, preferably from 10 to 20 50p.m, such as 20 to 30p,m. Suitable organic polymeric materials include polyethylene, polypropylene, polyvinyl chloride and polyethylene terephthalate.
Suitably, the base sheet and lid comprise different materials.
2s In another aspect, the material comprising the desiccant is an organic polymeric plastic having particular characteristics e.g. a thermoplastic.
In yet another aspect, the organic polymeric plastic is a polyamide.
Preferably the desiccant is selected from the group consisting of silica gel, zeolite, aiumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve and any mixtures thereof.
In one aspect, the container additionally comprises a medicament in dry powder form. Suitably, the medicament is suitable for the treatment of respiratory disorders.
Preferably, the medicament is salmeterol xinafoate, fluticasone propionate or a combination thereof.
to In another aspect of the present invention there is provided a method of reducing water ingress into a medicament powder comprising using a container for a medicament powder according to any of the preceding claims.
In another aspect of the present invention there is provided a package for storage of is a container for a medicament powder formed from a material capable of controlling the ingress of moisture thereto or egress or moisture therefrom.
In one aspect, the material is impermeable to moisture.
2o In another aspect, the material controls the ingress or egress of moisture such that the ambient moisture content within the package is essentially constant, such as varying by no more than ~20%, preferably by less than ~10%. Ambient moisture content may for example be measured by Relative Humidity within the package.
The preferred absolute level of moisture content will vary from medicament to 2s medicament but may be readily determined through laboratory testing.
In another aspect, the material enables moisture transfer in one way only i.e.
ingress only or egress only.
In another aspect, the material enables moisture transfer to either a set minimum lmaximum moisture content within the package or within a set minimum / maximum moisture transfer rate.
s In another aspect, the material is also capable of controlling the flow of other gaseous or vapour form species. Tyvek (trade name) is a suitable material.
In one aspect, the package is wrappable and sealable around the container to form an enclosed volume in which the container is disposed, the package being to impermeable to water vapour, thereby substantially reducing ingress of water vapour and particulate matter into said enclosed volume.
In another aspect, the package additionally comprises a desiccant within the enclosed volume.
is Preferably the desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve and any mixtures thereof.
2o In one aspect the package includes at least one heat sealable layer and at least one layer of a metal foil.
In another aspect, the metal comprising said metal foil is selected from the group consisting of aluminium, tin, iron, zinc and magnesium.
In yet another aspect, the package includes protective layers located on the outside of the package.
In one aspect, the protective layer comprises a polyester film and the heat sealable layer comprises an ionomer film.
In another aspect of the present invention there is provided a method of storing a container for a medicament powder comprising providing a packaging material which is capable of controlling the flow of water vapour; filling a container with a medicament powder; wrapping said container with said package material to form an enclosed volume in which said container is disposed therein; and sealing the package.
In yet another aspect, the method additionally comprises providing a desiccant within the enclosed volume.
io In one aspect, the sealing comprises heat sealing said packaging material. In other aspects, the seal is formed by ultrasonic welding, heat stamping, adhesive or laser welding methods.
is In another aspect of the present invention there is provided a packaged container, comprising a container containing a medicament powder; and an overwrap package enclosing the container and a desiccant; wherein the container and the desiccant are sealable within the overwrap. Preferably the overwrap comprises a desiccant material and/or is lined, coated or impregnated with a desiccant material.
The overwrap package may be in the form of a shrink wrap or of a loose wrap e.g. in sachet form. Any spare volume within the overwrap may be evacuated or an inert gas such as nitrogen deliberately inserted.
2s fn another aspect of the present invention there is provided a packaged powder medicament dispenser (or reloadable cartridge therefor as described supra) comprising a medicament dispenser for a medicament powder; and an overwrap package enclosing the medicament dispenser, wherein the medicament dispenser are sealable within the overwrap. The overwrap package may comprise desiccant, 3o and or the package may have desiccant contained therewithin. The medicament dispenser may comprise a powder reservoir or a medicament carrier for containment of medicament.
Where the overwrap comprises desiccant it may be impregnated or otherwise s blended with material or added as a coating or a liner.
In another aspect, the body of said medicament dispenser also comprises a desiccant.
lo Preferably the desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve, zinc chloride, and any mixtures thereof.
In another aspect of the present invention there is provided a container for a is medicament powder formed.from a material capable of controlling the ingress of moisture thereto or egress or moisture therefrom.
In one aspect, the material is impermeable to moisture.
2o In another aspect, the material controls the ingress or egress of moisture such that the ambient moisture content within the package is essentially constant, such as varying by no more than ~20%, preferably by less than ~10%.
In another aspect, the material enables moisture transfer in one way only i.e.
ingress 2s only or egress only.
In another aspect, the material enables moisture transfer to either a set minimum /maximum moisture content within the package or within a set minimum / maximum moisture transfer rate.
In another aspect, the material is also capable of controlling the flow of other gaseous or vapour form species.
In other aspects, the medicament container or overwrap therefor or any part of a medicament dispenser for use therewith is comprised of a material having desiccant blended or otherwise loaded or impregnated therein. Suitable materials are described in PCT Application Nos. W099162697 and WO/00/17258 in the name of Capitol Speciality Plastics Inc.
to Suitable materials comprise a thermoplastic/desiccant blend. Examples of thermoplastics include polyolefin, polyethylene, polycarbonate, polyamide, ethylene-vinyl acetate copolymer, ethylene-methacrylate copolymer, polyvinyl chloride, polystyrene, polyester, polyester amide, polyacrylic ester, and polyvinylidene chloride, acrylic, polyurethane, polyacetal, and polycarbonate. These and other is thermoplastics may be utilized either singularly, or in combinations.
The concentration of desiccant entrained (e.g. mixed or blended) within the thermoplastic may exceed seventy-five percent (75%) to not greater than eighty percent (80%) by weight, so that about seventy-five percent (75%) may extend to ~2o eighty percent (80%) by weight. Typically, however, the desiccant concentration will fall within a range of forty to seventy-five percent (40-75%) desiccant to thermoplastic, by weight. This concentration is considered to be a high concentration for most thermoplastics. The maximum desiccant bearable concentrations will vary among the various types of thermoplastics due to their 2s differing characteristics. In the instance of polyethylene or polypropylene, for example, the maximum concentration of desiccant will be about seventy-five percent (75%) by weight. As the desiccant concentrations within the thermoplastics increase, the performance of the material degenerates to unacceptable levels.
At lower levels of desiccant concentrations, about forty percent (40%) could extend to 3o as low as thirty percent (30%) where the limits of a viable product are reached.
Brief Description of Invention Figure 1 shows a medicament carrier in the form of a capsule according to the s present invention.
Figure 2a is a cross-sectional side elevation of a single medicament blister strip impregnated with a desiccant according to the present invention.
to Figure 2b is a top perspective of a medicament blister strip illustrated in Figure 2a.
Figure 3a is a cross-sectional side elevation of a single medicament blister having a laminate comprising a desiccant according to the present invention.
zs Figure 3b is a top perspective of a medicament blister strip illustrated in Figure 3a.
Figure 4a is a cross-sectional side elevation of a single medicament blister having a ring containing a desiccant impregnated into the laminate surrounding the blister pocket.
Figure 4b is a top perspective of the medicament blister shown in Figure 4a.
Figure 5 shows a cross-sectional dry powder inhaler comprising a powder reservoir according the present invention.
Figure 6 shows a cross-sectional dry powder inhaler comprising a medicament carrier according to the present invention.
Figure 7 is a top perspective of a package for storing a dry powder inhaler according 3o to the present invention.
Figure 8 is a side perspective of the package of Figure 7.
Figure 9 is a cat-away bottom perspective of the package for storing a dry powder inhaler according to the present invention.
s Figure 10 is a cross-sectional view of the package for storing a dry powder inhaler according to the present invention.
1o Detailed Description of the Drawings The medicament carrier in Figure 1 is in the-form of a capsule 1 comprising a wall 2 enclosing medicament powder 5. The wall 2 comprises a desiccant 3 which reduces or otherwise controls moisture ingress into the capsule 1 during storage and/or when is in situ within the body of the inhaler (not shown). Medicament powder 5 is released on piercing the wall 2 of capsule 1 and may be inhaled by a patient.
Figure 2a shows a sectional side-elevation of a single blister strip 106 comprising a pocket 107, containing dry powder 105, base 110 and lid comprising laminates 114, 20 115. The lid is composed of a metallic foil laminate 114 bound to a plastic laminate 115. In the diagram, the lid 114, 115 is hermetically sealed to base 110 by appropriate means (e.g. adhesion, welding). Base 110 comprises an organic polymeric plastic impregnated with desiccant 103. In use, the desiccant absorbs any moisture which permeates through the lid 114, 115 and base 110, maintaining the 2s powder 105 in a dry condition until the lid 114, 115 is removed from the base 110.
A top perspective of the blister strip 106 showing pockets 107 is illustrated in Figure 2b. Laminated lid 114, 115 is sealed to base 110 which is impregnated with desiccant 103.
Figure 3a shows a cross-sectional elevation of a different single blister strip 206 according to the invention. The blister strip 206 is composed of several laminated sheets, the lid .being formed from metallic foil 214 and plastic laminate 215 while the base comprises plastic laminates 210 and 211. The plastic laminate 211 comprises s a desiccant material 203 for absorbing any moisture which permeates through laminated sheets 214, 215 and 210, thereby reducing ingress into medicament powder 205 within pocket 207.
Figure 3b is a top perspective of a blister strip 206 showing several blisters as io described in Figure 3a. Metallic foil 214 and plastic laminate 215 form a lid which is hermetically sealed, by appropriate adhesive or welding means, to the base of strip 206. The base comprises plastic laminates 210 and 211, laminate 211 being disposed on the internal surface of pocket 207 and comprising a desiccant.
is Figure 4a shows a cross-sectional elevation of yet another single blister strip 306 according to the invention. Metallic foil 314 and plastic laminate 315 form a lid for base 310 which are hermetically sealed together to reduce moisture ingress into pocket 307 containing medicament powder 305. The circumference of pocket 307 is surrounded by a ring 319, within base 310, comprising desiccant 303 which absorbs 2o moisture which permeates into the blister, particularly between lid sheet 315 and base sheet 310.
A plan perspective of the single blister strip 314 shown in Figure 4a is illustrated in Figure 4b. The ring 319 of material comprising desiccant 303 surrounds pocket 2s thereby absorbing any moisture which permeates into the pocket 307 through foil 314 and laminates 315 and/or base sheet 310, together with moisture ingress between lid and base sheets 315, 310.
Figure 5 shows a sectional view of a dry powder inhaler 420 according to the present 3o invention. The inhaler 420 comprises a body 421 which defines a reservoir 423 and a reservoir cover 424. The reservoir contains a supply of medicament in dry powder form 405. The walls 423 of the reservoir, defined by the body 421, are comprised of a desiccant material 403. Base 425 and body 421 define an aperture 430 through which powder.405 can pass from the reservoir to the dosing member 432. Powder 405 is guided by the walls 423 of the reservoir, which form a hopper, to the dosing s member 432. Extending laterally from the tower end of the main body 421 is mouthpiece 435, through which the patient inhales via passage 433. If the device were intended for nasal inhalation this would be replaced by a nosepiece. The desiccant material 403, comprising walls 423, reduce moisture absorption by medicament powder 405. Optionally a desiccant comprising material may be io located within the walls of passage 433 and/or a ring of same material around the metering valve (not shown) which controls the flow of medicament into passage 433.
Figure 6 shows a simplified cross-sectional plan view of a dry powder inhaler comprising a medicament carrier according to the present invention. The inhaler is 540 dispenses unit doses of medicament powder from a medicament blister strip 506. The inhaler is comprised of an outer casing 544 enclosing a medicament strip 506 within body 521. The medicamenfi strip may be, for example, any of those described in Figures 2a to 4b above. The internal walls of body 521 are comprised of a desiccant material (not shown) which reduce the levels of moisture within the 2o internal cavity of the inhaler, thereby protecting the medicament powder within strip 506. The patient uses the inhaler by holding the device to his mouth, depressing lever 538, and inhaling through mouthpiece 535: Depression of lever 538 activates the internal mechanism of the inhaler, such that the lid 514 and base 510 sheets of coiled medicament blister strip 506 are separated at index wheel 541 by use of 2s contracting wheel 542 and base wheel 543. A unit dose of powdered medicament within blister pocket 507 is released and may be inhaled by the patient through exit port 533 and mouthpiece 535.
Figure 7 shows a top perspective of a container storage system for storing a dry 3o powder inhaler or cartridge refill therefor according to the present invention. The container storage system 650 includes a package or wrapping 652 that employs mufti-layers of material 970, 972, 974. (See Figure 10.) The package 652 further includes fin seams 654, 656 which are disposed along two parallel side edges of the package and along a single longitudinal edge of the package 652. The package comprises a desiccant material, or alternatively is lined, coated or impregnated with a desiccant material.
The number and type of fin seams 654, 656 are not limited to the types shown in the drawings. The package 652 can. include additional seams or significantly fewer seams such as a continuous single seam. The orientation of the seams 654, 656 is io not limited to the orientation shown in the drawings. The orientation of the seams 654, 656 is typically a function of the sealing device and such seams may be oriented in a manner which substantially increases manufacturing efficiency.
During manufacture, the longitudinal seam 654 may be formed first by heat sealing and the two end seams 656 may then be formed by heat sealing to close the package.
is Other types of seams include, but are not limited to, gusset type seams which include excess material which provides expansibility, stitched type seams, or mechanically crimped seams, and other like structures.
The container storage system includes a dry powder inhaler 820 (see Figure 9).
2o While the preferred inhaler is a dry powder inhaler 820, other dry powder inhalers (such as that described in Figure 6) are not beyond the scope of the present invention.
Figure 8 shows a side perspective of the container storage system of Figure 7.
The 2s fin seams 654 and 656 in Figure 7 are formed by a conventional heat sealing device which mechanically crimps sides of the package 750 together while simultaneously providing heat to the sides 654, 656/756 (Figures 7 and 8). The heat sealing device typically has electrical heater elements shaped to produce the pattern of the fin seams 654, 656!756 where the fin seams include multiple ridges 658/758. The 3o sealing mechanism of the container storage system 650/750 of the present invention is not limited to heat sealing devices. Other sealing devices include, but are not limited to, glue sealing machines, sonic welding machines, electron beam radiation machines, and other like sealing devices.
As shown in Figure 7, the package 750 preferably has a substantially rectangular s configuration with a substantially elliptical cross section, however, other shapes of the package 750 are not beyond the scope of the present invention. Other shapes include, but are not limited to circular, square, triangular, trapezoidal, pentagonal, hexagonal, octagonal, and other like shapes. The shape of the package 750 is preferably a function of the shape of the enclosed medicament powder container to as well as the amount and type of storage space since the package 752 is made from flexible materials as will be described in further detail below.
Figure 9 shows a cut-away bottom perspective of the package for storing a dry powder inhaler according to the present invention. The package 852 provides an is enclosed volume 860 in which the inhaler 820 is disposed therein. The size of the enclosed volume 860 can be adjusted according to the size of the inhaler 820 and related parts thereto. Preferably, the enclosed volume 860 is of a size which permits relative ease of closing respective sides and layers 852, 2fi and 28 without substantial stretching of the package 852. The enclosed volume 860 may be 2o substantially evacuated prior to formation of the fin seams 858, 854 (not shown) to substantially reduce any water vapour being present in the enclosed volume 860.
The enclosed volume 860 may be evacuated to such a degree that the enclosed volume 860 is a vacuum region around the medicament inhaler 820. While the enclosed volume 860, may remain constant, its relative shape may change 2s according to shifting of the inhaler 820 disposed within the enclosed volume 860.
In a preferred embodiment, a porous container of moisture absorbing material lays adjacent to the mouthpiece 835 in a loose or free flowing manner.
Alternatively, the moisture absorbing material 862 can be secured to the inside of the flexible package. In another alternative embodiment, the moisture absorbing container 3o may be attached to a bracket structure such as a ring which is fastened to the inhaler 820.
In one possible embodiment, the moisture absorbing material may be attached to the external surface of the mouthpiece 835 by a fastening device such as a rubber band 863. The fastening device 863 is preferably a removable elastic mechanism such as a rubber band. However, other fastening devices are not beyond the scope of the present invention. Other fastening devices include, but are not limited to, adhesives, adhesive tapes, shrink-wrap plastic, fasteners such as screws, nails, or rivets, compartments which are part of the mouthpiece housing 46, and other like attachment devices. In an alternative embodiment (not shown), a plurality of beads to of material comprising a desiccant may be placed within the enclosed space 860.
Similarly, other carriers comprised of a desiccant material may be enclosed within space 860 to absorb excess moisture from the enclosure.
Figure 10 is a cross-sectional view of the package for storing a dry powder inhaler is according to the present invention. The amorphous shape of the enclosed volume 960 is attributed to the flexible materials which make up the layers 970, 972, 974 of the package 952. The enclosed volume 960 can be varied in size such that it substantially conforms to the shape of the inhaler and any related parts thereto or such that the enclosed volume 960 is larger than the inhaler 820, as shown in Figure 20 9. When the enclosed volume is of a size which is substantially equivalent with the surface area of the inhaler 820 and related parts, the layers 970, 972, and 974 of material substantially conform to the shape of the inhaler and related parts.
The package is preferably placed in a separate, more rigid container, such as a paperboard or cardboard box (not shown) typically used in the pharmaceutical 2s industry. The package may expand during storage due to slow leakage of volatiles from the plastics constituting the body of the inhaler. In this situation, the shape of the package may conform to some extent to the internal shape of the rigid container if the volume of the rigid container is just slightly larger than the expanded volume of the flexible package.
Flexible Packaging Materials The flexible packaging material can be any material which is impervious to or substantially impervious to moisture. The packaging material is preferably permeable to volatiles which may escape from the plastics forming the body of the inhaler and/or the medicament carrier, by diffusion or otherwise, thereby preventing a build-up in pressure.
For ease of manufacturing, and in order to provide the necessary properties to the io packaging material, the flexible packaging material preferably comprises a non-thermoplastic substrate (such as a metal foil) and a heat sealable Payer disposed thereon, and an additional protective layer, such as a polymer film of polyester. The heat sealable layer is usually disposed on the inner surface of the assembled package. The additional protective layer is usually disposed on the surface opposite is the heat sealable layer. An example of a particularly useful foil laminate is a polyester film adhesively laminated to aluminium foil adhesively laminated to lonomer (SURLYNT"") film, for example, 12p polyester/9p aluminum/50p ionomer film supplied by Lawson Mardon Singen (LMS). To further reduce moisture ingress, thicker metal films, such as 20 to 25 p, may be used.
The substrate is preferably formed from aluminium foil. However, other metals for the substrate include, but are not limited to, tin, iron, zinc, or magnesium formed on a sheet by vacuum deposition or sputtering and a carboxyl group-containing polyolefin layer formed on the metal layer by lamination.
The heat sealable layer can be formed from any thermoplastic or thermosetting material such as an ionomer resin, polyolefin, or cycloolefin copolymer.
lonomer resins typically include ionically cross- linked ethylene-methacrylic acid and ethylene acrylic acid copolymers. Properties which distinguish these ionomers resins from other polyolefin heat-sealed polymers are high clarity, high impact resistance, low haze in lamination, tear resistance, abrasion resistance, solid state toughness, and moisture imperviousness. In the preferred embodiment, the heat sealable layer is made out of SURLYNT"" (an ionomer resin) or a form of polyethylene to provide sufficient heat sealing properties.
The outer protective layer, if present, can be formed of any material as long as the final laminate has the requisite properties.
Preferably, the protective layer (e.g., polyester) is adhesively laminated to the substrate (e.g., aluminium) and the substrate layer in turn is adhesively laminated to Io the heat sealable layer (e.g., the ionomer film or SURLYNT"" (an ionomer resin)).
Preferred exemplary thicknesses of the three layers include a protective layer 1 to 40, preferably 4 to 30, more preferably 10 to 23 microns, and most preferably microns; a substrate layer of 1 to 100, preferably 3 to 70, more preferably 5 to 50 microns, more preferably 6 to 20 microns, and most preferably 9 microns. For the is heat sealable layer, preferred exemplary thicknesses include thicknesses of 1 to 100, preferably 5 to 70, more preferably 10 to 60, more preferably 20 to 55 microns, and most preferably 50 microns.
Adhesives may be used to join the respective layers of materials together. The 2o adhesive layers are typically substantially smaller in thickness relative to the thickness of the substrate, heat sealable and/or protective layers which they bond.
The number, size, and shape of the layers are not limited to those layers shown in the drawings. Any number of layers with relative areas of any size and predetermined thicknesses may be used so long as the flexible package forms an 2s enclosed volume which substantially prevents ingression of water vapour and particulate matter into the enclosed volume while permitting egression out of the enclosed volume of any volatile released from the plastics used in the body of the inhaler or the medicament carrier. The size, shape, and number of layers of the package are typically a function of the size and contents of the inhaler and/or 3o medicament carrier.
The package is believed to operate similarly to a virtual one-way valve due to the composition of the layers and due to the transmission rate of water vapour molecules into, the enclosed volume relative to the transmission rate of gas molecules of a plastic volatile, such as formaldehyde, out of the enclosed volume.
s The package permits the volatile to diffuse out of the enclosed volume while substantially preventing water vapour and other particulate matter from entering the enclosed volume. Excess or leakage of the volatile is permitted to egress from the package. The virtual one-way valve function of the package prevents or minimizes the chance of any sudden ruptures or prevents or minimizes unexpected expulsion to of the plastic volatile during opening of the package.
Moisture Absorbing Materials The moisture absorbing material is preferably a silica gel desiccant sachet.
is However, other vapour or moisture absorbing mechanisms are not beyond the scope of the present invention. Other vapour or moisture absorbing materials include desiccants made from inorganic materials such a zeolites and aluminas. Such inorganic materials of vapour or moisture absorbing materials have high water absorption capacities and favourable water absorption isotherm shapes. The water 2o absorption capacity of such materials typically varies from 20 to 50 weight percent.
In the preferred embodiment, the absorbing material is a MINIPAX~supplied by Multisorb Technologies in the United States and Silgelac in Europe (silica gel packaged inside TYVEK°, which is a nylon mesh bonded with a microporous polyurethane). Other exemplary moisture absorbing materials include, but are not 2s limited to, alumina, bauxite, anhydrous, calcium sulphate, water-absorbing clay, activated bentonite clay, a molecular sieve, or other like materials which optionally include a moisture sensitive colour indicator such as cobalt chloride to indicate when the desiccant is no longer operable. While in the preferred embodiment of the present invention, the package is designed to substantially prevent ingression of 3o water vapour and particulate matter into the enclosed volume, the moisture absorbing material is placed within the enclosed volume in order to absorb any residual moisture present in the atmosphere or on the external surface of the pressurized container or mouthpiece or a combination thereof, prior to sealing the package. .
s The desiccant should be present in an amount sufficient to absorb any residual moisture inside the package. When silica gel is used, 1 g to 10g of silica gel is sufficient for a typical dry powder inhaler. Moreover, the desiccant should be present in an amount sufificient to absorb any moisture that possibly ingresses from the external environment. It is also possible to place the desiccant inside the to container, either loose in the canister or as part of an assembly attached to the canister.
Alledicaments is Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate (eg s the sodium salt), ketotifen or nedocromil (eg as the sodium salt); antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., 2o methapyrilene; anti- inflammatories, e.g., beclomethasone (eg as the dipropionate ester), fluticasone (eg as the propionate ester), flunisolide, budesonide, rofleponide, mometasone eg as the furoate ester), ciclesonide, triamcinolone (eg as the acetonide) or 6a, 9a-difluoro-11 (i-hydroxy-16a-methyl-3-oxo-17a-propionyloxy-androsta-1,4-diene-17[i-carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester;
2s antitussives, e.g., noscapine; bronchodilators, e.g., albuterol (eg as free base or sulphate), salmeterol (eg as xinafoate), ephedrine, adrenaline, fenoterol (eg as hydrobromide), formoterol (eg as fumarate), isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol (eg as acetate), reproterol (eg as hydrochloride), rimiterol, terbutaline (eg as sulphate), isoetharine, tulobuterol or 4-3o hydroxy-7-[2-[(2-[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl-2(3H)-benzothiazolone; adenosine 2a agonists, eg 2R,3R,4S,5R)-2-[6-Amino-2-(1 S-hydroxymethyl-2-phenyl-ethylamino)-purin-9-yl]-5-(2-ethyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol (e.g. as maleate); aa. integrin inhibitors eg (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl~oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy) acetyl]amino}pentanoyl)amino] propanoic acid (e.g as free acid or s potassium salt), diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium (eg as bromide), tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon; vaccines, diagnostics, and gene therapies. It will to be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.
is Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
Medicaments can also be delivered in combinations. Preferred formulations 2o containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) or formoterol (eg as the fumarate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate) or budesonide. A particularly preferred combination is a combination of 2s fluticasone propionate and salmeterol, or a salt thereof (particularly the xinafoate salt). A further combination of particular interest is budesonide and formoterol (e.g.
as the fumarate salt).
It may be appreciated that any of the parts of the medicament container used 3o therewith which contact the medicament may be coated with materials such as fluoropolymer materials which reduce the tendency of medicament to adhere thereto. Suitable fluoropolymers include polytetrafluoroethylene (PTFE) and fluoroethylene propylene (FEP). Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.
1o The application of which this description and claims form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described therein. They may take the form of product, method or use claims and may include, by way of example and without limitation, one or more of the following ~s claims:
Technical Field The present invention relates to containers and dispensers for medicament powders.
In particular, the invention relates to dry powder inhalation dispensers and components thereof which substantially alleviate or reduce moisture build-up therein.
The invention also relates to a method for reducing moisture ingress inside a dry io powder inhaler.
Background to the Invention Is Medicaments for treating respiratory disorders are frequently administered as dry powder formulations through the mouth and nose. Dry powder medicament dispensers, such as inhalers, are used in the administration of these drugs, inhalation by the patient resulting in uptake of a specified dosage of medicament through the nose or mouth. The drug may be stored as a dry powder within a 2o reservoir in the body of the inhaler, a metering chamber being utilised to administer a specified dose of medicament. Alternatively, more sophisticated medicament dispensers employ medicament carriers, such as individual capsules or blister packs/strips containing defined doses of powdered drug.
2s Patients often rely on medication delivered by dry powder inhalers for rapid treatment of respiratory disorders that are debilitating and in some cases life threatening. It is, therefore, essential that the prescribed dose of drug is delivered accurately and consistently to meet the patient's needs and comply with the requirements of regulatory authorities.
A problem which can occur in the storage and product lifetime of an inhaler is ingress of moisture into the medicament powder. A build-up of moisture can prevent the administration of an effective dose of medicament by causing an increase in particle size and/or adherence of hygroscopic particles to the walls of the carrier or s device, thereby leading to reduced uptake via inhalation by the patient. fn extreme cases, depending upon the chemical nature of the medicament, moisture build-up may lead to degradation of the drug.
Another problem can be microbial contamination, which is often assisted by the to undesirable presence of excess moisture.
The Applicants have found that the inclusion of a desiccant in the body of the inhaler or the walls of the medicament carrier can significantly improve the aforementioned problems. Furthermore, storage of the inhaler or medicament carrier within a sealed Is package incorporating a desiccant, can markedly reduce moisture ingress.
The Applicants has also found that the aforementioned problems can be ameliorated by controlling the ingress of moisture to, or egress of moisture from, the medicament container. Control may be achieved by either suitable choice of container materials 20 or by enclosure of the container or a dispenser including the container in a suitable package. The control need not absolutely prevent moisture transfer. Indeed, the Applicants have found that under certain conditions a limited degree of moisture transfer can be desirable.
2s WO 99/32180 teaches the inclusion of moisture permeable chambers containing desiccants within a blister pack. US patent 5,740,793 discloses the inclusion of a desiccant cartridge within an inhaler or the medicament carrier cassette. US
patent 5,394,868 describes a chamber within a powder inhaler for holding a desiccating substance. The use of desiccant filters within medicament dispensers is described 3o in US patents 5,687,746 and 5,775,320, and PCT patent application no. WO
01348.
Summary ofi Invention s According to the present invention, there is provided a container for a medicament powder formed from a material comprising a desiccant.
In one aspect, the container is suitable for containing a measured dose of medicament. Packs in blister pack form for the containment of a unit dose Io medicaments are envisaged, as are packs containing multiple unit dose blisters arranged sequentially or otherwise, such as in series form. A particular multi-unit dose arrangement comprises an elongate strip having multiple blisters arranged in series thereon.
Is In another aspect, the container is a reservoir for dry powder medicament.
Metering means are provided to enable metering of dose from the reservoir and transport of that dose to a delivery position.
In one aspect, the container is a medicament dispenser comprising a body defining a 2o reservoir for medicament in powder form, and an outlet in communication with said reservoir for release of the medicament. In one aspect, the device is an inhaler and the outlet is one through which a user can inhale.
In another aspect, the container is in the form of a reloadable cartridge comprising a 2s medicament pack (e.g. in multi-unit dose blister form or reservoir form).
The cartridge is shaped and sized for receipt by a medicament delivery device (e.g. an inhaler device).
In another aspect, the container is a medicament dispenser comprising a body 3o defining a chamber for receipt of a medicament carrier, and an outlet in communication with said chamber for release of the medicament. In one aspect, the device is an inhaler and the outlet is one through which the user can inhale.
In yet another aspect, the body consists of the material comprising the desiccant.
s In one aspect, the body comprises the material comprising the desiccant.
In another aspect, the material comprising the desiccant coats the body e.g.
part or whole of the inside of the body.
io In yet another aspect, the material comprising the desiccant is impregnated throughout the body.
In one aspect, the material comprising the desiccant lines the body (e.g. the interior Is of the body which contacts the medicament powder in use).
Optionally the desiccant comprising material may be located around a seal for sealing the reservoir or medicament carrier optionally the seal (e.g. in the form of a sealing ring) may itself comprise or consist of a desiccant.
In another aspect, the container is a medicament carrier.
In yet another aspect, the medicament carrier is a capsule comprising a wall enclosing the medicament.
In one aspect, the medicament carrier is a blister pack comprising a base sheet and a lid.
In another aspect, the medicament carrier comprises a material comprising a 3o desiccant.
In yet another aspect, the material comprising the desiccant coats the wall, or the base sheet, or the lid of the medicament carrier.
fn one aspect, the material comprising the desiccant impregnates the wall, or base s sheet, or lid of the medicament carrier.
In another aspect, the material comprising the desiccant lines the wall, or base sheet, or lid of the medicament carrier.
to In another aspect, the material comprising the desiccant is moulded into the wall, or base sheet, or lid of the medicament carrier.
In yet another aspect, a well containing desiccant surrounds individual pockets in the blister packs.
is In one aspect, the blister pack comprises a laminate comprising a desiccant.
Suitably, the laminate comprises material selected from the group consisting of metal foil, organic polymeric material and paper. Suitable metal foils include aluminium or tin foil having a thickness of from 5 to 100p,m, preferably from 10 to 20 50p.m, such as 20 to 30p,m. Suitable organic polymeric materials include polyethylene, polypropylene, polyvinyl chloride and polyethylene terephthalate.
Suitably, the base sheet and lid comprise different materials.
2s In another aspect, the material comprising the desiccant is an organic polymeric plastic having particular characteristics e.g. a thermoplastic.
In yet another aspect, the organic polymeric plastic is a polyamide.
Preferably the desiccant is selected from the group consisting of silica gel, zeolite, aiumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve and any mixtures thereof.
In one aspect, the container additionally comprises a medicament in dry powder form. Suitably, the medicament is suitable for the treatment of respiratory disorders.
Preferably, the medicament is salmeterol xinafoate, fluticasone propionate or a combination thereof.
to In another aspect of the present invention there is provided a method of reducing water ingress into a medicament powder comprising using a container for a medicament powder according to any of the preceding claims.
In another aspect of the present invention there is provided a package for storage of is a container for a medicament powder formed from a material capable of controlling the ingress of moisture thereto or egress or moisture therefrom.
In one aspect, the material is impermeable to moisture.
2o In another aspect, the material controls the ingress or egress of moisture such that the ambient moisture content within the package is essentially constant, such as varying by no more than ~20%, preferably by less than ~10%. Ambient moisture content may for example be measured by Relative Humidity within the package.
The preferred absolute level of moisture content will vary from medicament to 2s medicament but may be readily determined through laboratory testing.
In another aspect, the material enables moisture transfer in one way only i.e.
ingress only or egress only.
In another aspect, the material enables moisture transfer to either a set minimum lmaximum moisture content within the package or within a set minimum / maximum moisture transfer rate.
s In another aspect, the material is also capable of controlling the flow of other gaseous or vapour form species. Tyvek (trade name) is a suitable material.
In one aspect, the package is wrappable and sealable around the container to form an enclosed volume in which the container is disposed, the package being to impermeable to water vapour, thereby substantially reducing ingress of water vapour and particulate matter into said enclosed volume.
In another aspect, the package additionally comprises a desiccant within the enclosed volume.
is Preferably the desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve and any mixtures thereof.
2o In one aspect the package includes at least one heat sealable layer and at least one layer of a metal foil.
In another aspect, the metal comprising said metal foil is selected from the group consisting of aluminium, tin, iron, zinc and magnesium.
In yet another aspect, the package includes protective layers located on the outside of the package.
In one aspect, the protective layer comprises a polyester film and the heat sealable layer comprises an ionomer film.
In another aspect of the present invention there is provided a method of storing a container for a medicament powder comprising providing a packaging material which is capable of controlling the flow of water vapour; filling a container with a medicament powder; wrapping said container with said package material to form an enclosed volume in which said container is disposed therein; and sealing the package.
In yet another aspect, the method additionally comprises providing a desiccant within the enclosed volume.
io In one aspect, the sealing comprises heat sealing said packaging material. In other aspects, the seal is formed by ultrasonic welding, heat stamping, adhesive or laser welding methods.
is In another aspect of the present invention there is provided a packaged container, comprising a container containing a medicament powder; and an overwrap package enclosing the container and a desiccant; wherein the container and the desiccant are sealable within the overwrap. Preferably the overwrap comprises a desiccant material and/or is lined, coated or impregnated with a desiccant material.
The overwrap package may be in the form of a shrink wrap or of a loose wrap e.g. in sachet form. Any spare volume within the overwrap may be evacuated or an inert gas such as nitrogen deliberately inserted.
2s fn another aspect of the present invention there is provided a packaged powder medicament dispenser (or reloadable cartridge therefor as described supra) comprising a medicament dispenser for a medicament powder; and an overwrap package enclosing the medicament dispenser, wherein the medicament dispenser are sealable within the overwrap. The overwrap package may comprise desiccant, 3o and or the package may have desiccant contained therewithin. The medicament dispenser may comprise a powder reservoir or a medicament carrier for containment of medicament.
Where the overwrap comprises desiccant it may be impregnated or otherwise s blended with material or added as a coating or a liner.
In another aspect, the body of said medicament dispenser also comprises a desiccant.
lo Preferably the desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve, zinc chloride, and any mixtures thereof.
In another aspect of the present invention there is provided a container for a is medicament powder formed.from a material capable of controlling the ingress of moisture thereto or egress or moisture therefrom.
In one aspect, the material is impermeable to moisture.
2o In another aspect, the material controls the ingress or egress of moisture such that the ambient moisture content within the package is essentially constant, such as varying by no more than ~20%, preferably by less than ~10%.
In another aspect, the material enables moisture transfer in one way only i.e.
ingress 2s only or egress only.
In another aspect, the material enables moisture transfer to either a set minimum /maximum moisture content within the package or within a set minimum / maximum moisture transfer rate.
In another aspect, the material is also capable of controlling the flow of other gaseous or vapour form species.
In other aspects, the medicament container or overwrap therefor or any part of a medicament dispenser for use therewith is comprised of a material having desiccant blended or otherwise loaded or impregnated therein. Suitable materials are described in PCT Application Nos. W099162697 and WO/00/17258 in the name of Capitol Speciality Plastics Inc.
to Suitable materials comprise a thermoplastic/desiccant blend. Examples of thermoplastics include polyolefin, polyethylene, polycarbonate, polyamide, ethylene-vinyl acetate copolymer, ethylene-methacrylate copolymer, polyvinyl chloride, polystyrene, polyester, polyester amide, polyacrylic ester, and polyvinylidene chloride, acrylic, polyurethane, polyacetal, and polycarbonate. These and other is thermoplastics may be utilized either singularly, or in combinations.
The concentration of desiccant entrained (e.g. mixed or blended) within the thermoplastic may exceed seventy-five percent (75%) to not greater than eighty percent (80%) by weight, so that about seventy-five percent (75%) may extend to ~2o eighty percent (80%) by weight. Typically, however, the desiccant concentration will fall within a range of forty to seventy-five percent (40-75%) desiccant to thermoplastic, by weight. This concentration is considered to be a high concentration for most thermoplastics. The maximum desiccant bearable concentrations will vary among the various types of thermoplastics due to their 2s differing characteristics. In the instance of polyethylene or polypropylene, for example, the maximum concentration of desiccant will be about seventy-five percent (75%) by weight. As the desiccant concentrations within the thermoplastics increase, the performance of the material degenerates to unacceptable levels.
At lower levels of desiccant concentrations, about forty percent (40%) could extend to 3o as low as thirty percent (30%) where the limits of a viable product are reached.
Brief Description of Invention Figure 1 shows a medicament carrier in the form of a capsule according to the s present invention.
Figure 2a is a cross-sectional side elevation of a single medicament blister strip impregnated with a desiccant according to the present invention.
to Figure 2b is a top perspective of a medicament blister strip illustrated in Figure 2a.
Figure 3a is a cross-sectional side elevation of a single medicament blister having a laminate comprising a desiccant according to the present invention.
zs Figure 3b is a top perspective of a medicament blister strip illustrated in Figure 3a.
Figure 4a is a cross-sectional side elevation of a single medicament blister having a ring containing a desiccant impregnated into the laminate surrounding the blister pocket.
Figure 4b is a top perspective of the medicament blister shown in Figure 4a.
Figure 5 shows a cross-sectional dry powder inhaler comprising a powder reservoir according the present invention.
Figure 6 shows a cross-sectional dry powder inhaler comprising a medicament carrier according to the present invention.
Figure 7 is a top perspective of a package for storing a dry powder inhaler according 3o to the present invention.
Figure 8 is a side perspective of the package of Figure 7.
Figure 9 is a cat-away bottom perspective of the package for storing a dry powder inhaler according to the present invention.
s Figure 10 is a cross-sectional view of the package for storing a dry powder inhaler according to the present invention.
1o Detailed Description of the Drawings The medicament carrier in Figure 1 is in the-form of a capsule 1 comprising a wall 2 enclosing medicament powder 5. The wall 2 comprises a desiccant 3 which reduces or otherwise controls moisture ingress into the capsule 1 during storage and/or when is in situ within the body of the inhaler (not shown). Medicament powder 5 is released on piercing the wall 2 of capsule 1 and may be inhaled by a patient.
Figure 2a shows a sectional side-elevation of a single blister strip 106 comprising a pocket 107, containing dry powder 105, base 110 and lid comprising laminates 114, 20 115. The lid is composed of a metallic foil laminate 114 bound to a plastic laminate 115. In the diagram, the lid 114, 115 is hermetically sealed to base 110 by appropriate means (e.g. adhesion, welding). Base 110 comprises an organic polymeric plastic impregnated with desiccant 103. In use, the desiccant absorbs any moisture which permeates through the lid 114, 115 and base 110, maintaining the 2s powder 105 in a dry condition until the lid 114, 115 is removed from the base 110.
A top perspective of the blister strip 106 showing pockets 107 is illustrated in Figure 2b. Laminated lid 114, 115 is sealed to base 110 which is impregnated with desiccant 103.
Figure 3a shows a cross-sectional elevation of a different single blister strip 206 according to the invention. The blister strip 206 is composed of several laminated sheets, the lid .being formed from metallic foil 214 and plastic laminate 215 while the base comprises plastic laminates 210 and 211. The plastic laminate 211 comprises s a desiccant material 203 for absorbing any moisture which permeates through laminated sheets 214, 215 and 210, thereby reducing ingress into medicament powder 205 within pocket 207.
Figure 3b is a top perspective of a blister strip 206 showing several blisters as io described in Figure 3a. Metallic foil 214 and plastic laminate 215 form a lid which is hermetically sealed, by appropriate adhesive or welding means, to the base of strip 206. The base comprises plastic laminates 210 and 211, laminate 211 being disposed on the internal surface of pocket 207 and comprising a desiccant.
is Figure 4a shows a cross-sectional elevation of yet another single blister strip 306 according to the invention. Metallic foil 314 and plastic laminate 315 form a lid for base 310 which are hermetically sealed together to reduce moisture ingress into pocket 307 containing medicament powder 305. The circumference of pocket 307 is surrounded by a ring 319, within base 310, comprising desiccant 303 which absorbs 2o moisture which permeates into the blister, particularly between lid sheet 315 and base sheet 310.
A plan perspective of the single blister strip 314 shown in Figure 4a is illustrated in Figure 4b. The ring 319 of material comprising desiccant 303 surrounds pocket 2s thereby absorbing any moisture which permeates into the pocket 307 through foil 314 and laminates 315 and/or base sheet 310, together with moisture ingress between lid and base sheets 315, 310.
Figure 5 shows a sectional view of a dry powder inhaler 420 according to the present 3o invention. The inhaler 420 comprises a body 421 which defines a reservoir 423 and a reservoir cover 424. The reservoir contains a supply of medicament in dry powder form 405. The walls 423 of the reservoir, defined by the body 421, are comprised of a desiccant material 403. Base 425 and body 421 define an aperture 430 through which powder.405 can pass from the reservoir to the dosing member 432. Powder 405 is guided by the walls 423 of the reservoir, which form a hopper, to the dosing s member 432. Extending laterally from the tower end of the main body 421 is mouthpiece 435, through which the patient inhales via passage 433. If the device were intended for nasal inhalation this would be replaced by a nosepiece. The desiccant material 403, comprising walls 423, reduce moisture absorption by medicament powder 405. Optionally a desiccant comprising material may be io located within the walls of passage 433 and/or a ring of same material around the metering valve (not shown) which controls the flow of medicament into passage 433.
Figure 6 shows a simplified cross-sectional plan view of a dry powder inhaler comprising a medicament carrier according to the present invention. The inhaler is 540 dispenses unit doses of medicament powder from a medicament blister strip 506. The inhaler is comprised of an outer casing 544 enclosing a medicament strip 506 within body 521. The medicamenfi strip may be, for example, any of those described in Figures 2a to 4b above. The internal walls of body 521 are comprised of a desiccant material (not shown) which reduce the levels of moisture within the 2o internal cavity of the inhaler, thereby protecting the medicament powder within strip 506. The patient uses the inhaler by holding the device to his mouth, depressing lever 538, and inhaling through mouthpiece 535: Depression of lever 538 activates the internal mechanism of the inhaler, such that the lid 514 and base 510 sheets of coiled medicament blister strip 506 are separated at index wheel 541 by use of 2s contracting wheel 542 and base wheel 543. A unit dose of powdered medicament within blister pocket 507 is released and may be inhaled by the patient through exit port 533 and mouthpiece 535.
Figure 7 shows a top perspective of a container storage system for storing a dry 3o powder inhaler or cartridge refill therefor according to the present invention. The container storage system 650 includes a package or wrapping 652 that employs mufti-layers of material 970, 972, 974. (See Figure 10.) The package 652 further includes fin seams 654, 656 which are disposed along two parallel side edges of the package and along a single longitudinal edge of the package 652. The package comprises a desiccant material, or alternatively is lined, coated or impregnated with a desiccant material.
The number and type of fin seams 654, 656 are not limited to the types shown in the drawings. The package 652 can. include additional seams or significantly fewer seams such as a continuous single seam. The orientation of the seams 654, 656 is io not limited to the orientation shown in the drawings. The orientation of the seams 654, 656 is typically a function of the sealing device and such seams may be oriented in a manner which substantially increases manufacturing efficiency.
During manufacture, the longitudinal seam 654 may be formed first by heat sealing and the two end seams 656 may then be formed by heat sealing to close the package.
is Other types of seams include, but are not limited to, gusset type seams which include excess material which provides expansibility, stitched type seams, or mechanically crimped seams, and other like structures.
The container storage system includes a dry powder inhaler 820 (see Figure 9).
2o While the preferred inhaler is a dry powder inhaler 820, other dry powder inhalers (such as that described in Figure 6) are not beyond the scope of the present invention.
Figure 8 shows a side perspective of the container storage system of Figure 7.
The 2s fin seams 654 and 656 in Figure 7 are formed by a conventional heat sealing device which mechanically crimps sides of the package 750 together while simultaneously providing heat to the sides 654, 656/756 (Figures 7 and 8). The heat sealing device typically has electrical heater elements shaped to produce the pattern of the fin seams 654, 656!756 where the fin seams include multiple ridges 658/758. The 3o sealing mechanism of the container storage system 650/750 of the present invention is not limited to heat sealing devices. Other sealing devices include, but are not limited to, glue sealing machines, sonic welding machines, electron beam radiation machines, and other like sealing devices.
As shown in Figure 7, the package 750 preferably has a substantially rectangular s configuration with a substantially elliptical cross section, however, other shapes of the package 750 are not beyond the scope of the present invention. Other shapes include, but are not limited to circular, square, triangular, trapezoidal, pentagonal, hexagonal, octagonal, and other like shapes. The shape of the package 750 is preferably a function of the shape of the enclosed medicament powder container to as well as the amount and type of storage space since the package 752 is made from flexible materials as will be described in further detail below.
Figure 9 shows a cut-away bottom perspective of the package for storing a dry powder inhaler according to the present invention. The package 852 provides an is enclosed volume 860 in which the inhaler 820 is disposed therein. The size of the enclosed volume 860 can be adjusted according to the size of the inhaler 820 and related parts thereto. Preferably, the enclosed volume 860 is of a size which permits relative ease of closing respective sides and layers 852, 2fi and 28 without substantial stretching of the package 852. The enclosed volume 860 may be 2o substantially evacuated prior to formation of the fin seams 858, 854 (not shown) to substantially reduce any water vapour being present in the enclosed volume 860.
The enclosed volume 860 may be evacuated to such a degree that the enclosed volume 860 is a vacuum region around the medicament inhaler 820. While the enclosed volume 860, may remain constant, its relative shape may change 2s according to shifting of the inhaler 820 disposed within the enclosed volume 860.
In a preferred embodiment, a porous container of moisture absorbing material lays adjacent to the mouthpiece 835 in a loose or free flowing manner.
Alternatively, the moisture absorbing material 862 can be secured to the inside of the flexible package. In another alternative embodiment, the moisture absorbing container 3o may be attached to a bracket structure such as a ring which is fastened to the inhaler 820.
In one possible embodiment, the moisture absorbing material may be attached to the external surface of the mouthpiece 835 by a fastening device such as a rubber band 863. The fastening device 863 is preferably a removable elastic mechanism such as a rubber band. However, other fastening devices are not beyond the scope of the present invention. Other fastening devices include, but are not limited to, adhesives, adhesive tapes, shrink-wrap plastic, fasteners such as screws, nails, or rivets, compartments which are part of the mouthpiece housing 46, and other like attachment devices. In an alternative embodiment (not shown), a plurality of beads to of material comprising a desiccant may be placed within the enclosed space 860.
Similarly, other carriers comprised of a desiccant material may be enclosed within space 860 to absorb excess moisture from the enclosure.
Figure 10 is a cross-sectional view of the package for storing a dry powder inhaler is according to the present invention. The amorphous shape of the enclosed volume 960 is attributed to the flexible materials which make up the layers 970, 972, 974 of the package 952. The enclosed volume 960 can be varied in size such that it substantially conforms to the shape of the inhaler and any related parts thereto or such that the enclosed volume 960 is larger than the inhaler 820, as shown in Figure 20 9. When the enclosed volume is of a size which is substantially equivalent with the surface area of the inhaler 820 and related parts, the layers 970, 972, and 974 of material substantially conform to the shape of the inhaler and related parts.
The package is preferably placed in a separate, more rigid container, such as a paperboard or cardboard box (not shown) typically used in the pharmaceutical 2s industry. The package may expand during storage due to slow leakage of volatiles from the plastics constituting the body of the inhaler. In this situation, the shape of the package may conform to some extent to the internal shape of the rigid container if the volume of the rigid container is just slightly larger than the expanded volume of the flexible package.
Flexible Packaging Materials The flexible packaging material can be any material which is impervious to or substantially impervious to moisture. The packaging material is preferably permeable to volatiles which may escape from the plastics forming the body of the inhaler and/or the medicament carrier, by diffusion or otherwise, thereby preventing a build-up in pressure.
For ease of manufacturing, and in order to provide the necessary properties to the io packaging material, the flexible packaging material preferably comprises a non-thermoplastic substrate (such as a metal foil) and a heat sealable Payer disposed thereon, and an additional protective layer, such as a polymer film of polyester. The heat sealable layer is usually disposed on the inner surface of the assembled package. The additional protective layer is usually disposed on the surface opposite is the heat sealable layer. An example of a particularly useful foil laminate is a polyester film adhesively laminated to aluminium foil adhesively laminated to lonomer (SURLYNT"") film, for example, 12p polyester/9p aluminum/50p ionomer film supplied by Lawson Mardon Singen (LMS). To further reduce moisture ingress, thicker metal films, such as 20 to 25 p, may be used.
The substrate is preferably formed from aluminium foil. However, other metals for the substrate include, but are not limited to, tin, iron, zinc, or magnesium formed on a sheet by vacuum deposition or sputtering and a carboxyl group-containing polyolefin layer formed on the metal layer by lamination.
The heat sealable layer can be formed from any thermoplastic or thermosetting material such as an ionomer resin, polyolefin, or cycloolefin copolymer.
lonomer resins typically include ionically cross- linked ethylene-methacrylic acid and ethylene acrylic acid copolymers. Properties which distinguish these ionomers resins from other polyolefin heat-sealed polymers are high clarity, high impact resistance, low haze in lamination, tear resistance, abrasion resistance, solid state toughness, and moisture imperviousness. In the preferred embodiment, the heat sealable layer is made out of SURLYNT"" (an ionomer resin) or a form of polyethylene to provide sufficient heat sealing properties.
The outer protective layer, if present, can be formed of any material as long as the final laminate has the requisite properties.
Preferably, the protective layer (e.g., polyester) is adhesively laminated to the substrate (e.g., aluminium) and the substrate layer in turn is adhesively laminated to Io the heat sealable layer (e.g., the ionomer film or SURLYNT"" (an ionomer resin)).
Preferred exemplary thicknesses of the three layers include a protective layer 1 to 40, preferably 4 to 30, more preferably 10 to 23 microns, and most preferably microns; a substrate layer of 1 to 100, preferably 3 to 70, more preferably 5 to 50 microns, more preferably 6 to 20 microns, and most preferably 9 microns. For the is heat sealable layer, preferred exemplary thicknesses include thicknesses of 1 to 100, preferably 5 to 70, more preferably 10 to 60, more preferably 20 to 55 microns, and most preferably 50 microns.
Adhesives may be used to join the respective layers of materials together. The 2o adhesive layers are typically substantially smaller in thickness relative to the thickness of the substrate, heat sealable and/or protective layers which they bond.
The number, size, and shape of the layers are not limited to those layers shown in the drawings. Any number of layers with relative areas of any size and predetermined thicknesses may be used so long as the flexible package forms an 2s enclosed volume which substantially prevents ingression of water vapour and particulate matter into the enclosed volume while permitting egression out of the enclosed volume of any volatile released from the plastics used in the body of the inhaler or the medicament carrier. The size, shape, and number of layers of the package are typically a function of the size and contents of the inhaler and/or 3o medicament carrier.
The package is believed to operate similarly to a virtual one-way valve due to the composition of the layers and due to the transmission rate of water vapour molecules into, the enclosed volume relative to the transmission rate of gas molecules of a plastic volatile, such as formaldehyde, out of the enclosed volume.
s The package permits the volatile to diffuse out of the enclosed volume while substantially preventing water vapour and other particulate matter from entering the enclosed volume. Excess or leakage of the volatile is permitted to egress from the package. The virtual one-way valve function of the package prevents or minimizes the chance of any sudden ruptures or prevents or minimizes unexpected expulsion to of the plastic volatile during opening of the package.
Moisture Absorbing Materials The moisture absorbing material is preferably a silica gel desiccant sachet.
is However, other vapour or moisture absorbing mechanisms are not beyond the scope of the present invention. Other vapour or moisture absorbing materials include desiccants made from inorganic materials such a zeolites and aluminas. Such inorganic materials of vapour or moisture absorbing materials have high water absorption capacities and favourable water absorption isotherm shapes. The water 2o absorption capacity of such materials typically varies from 20 to 50 weight percent.
In the preferred embodiment, the absorbing material is a MINIPAX~supplied by Multisorb Technologies in the United States and Silgelac in Europe (silica gel packaged inside TYVEK°, which is a nylon mesh bonded with a microporous polyurethane). Other exemplary moisture absorbing materials include, but are not 2s limited to, alumina, bauxite, anhydrous, calcium sulphate, water-absorbing clay, activated bentonite clay, a molecular sieve, or other like materials which optionally include a moisture sensitive colour indicator such as cobalt chloride to indicate when the desiccant is no longer operable. While in the preferred embodiment of the present invention, the package is designed to substantially prevent ingression of 3o water vapour and particulate matter into the enclosed volume, the moisture absorbing material is placed within the enclosed volume in order to absorb any residual moisture present in the atmosphere or on the external surface of the pressurized container or mouthpiece or a combination thereof, prior to sealing the package. .
s The desiccant should be present in an amount sufficient to absorb any residual moisture inside the package. When silica gel is used, 1 g to 10g of silica gel is sufficient for a typical dry powder inhaler. Moreover, the desiccant should be present in an amount sufificient to absorb any moisture that possibly ingresses from the external environment. It is also possible to place the desiccant inside the to container, either loose in the canister or as part of an assembly attached to the canister.
Alledicaments is Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate (eg s the sodium salt), ketotifen or nedocromil (eg as the sodium salt); antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., 2o methapyrilene; anti- inflammatories, e.g., beclomethasone (eg as the dipropionate ester), fluticasone (eg as the propionate ester), flunisolide, budesonide, rofleponide, mometasone eg as the furoate ester), ciclesonide, triamcinolone (eg as the acetonide) or 6a, 9a-difluoro-11 (i-hydroxy-16a-methyl-3-oxo-17a-propionyloxy-androsta-1,4-diene-17[i-carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester;
2s antitussives, e.g., noscapine; bronchodilators, e.g., albuterol (eg as free base or sulphate), salmeterol (eg as xinafoate), ephedrine, adrenaline, fenoterol (eg as hydrobromide), formoterol (eg as fumarate), isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol (eg as acetate), reproterol (eg as hydrochloride), rimiterol, terbutaline (eg as sulphate), isoetharine, tulobuterol or 4-3o hydroxy-7-[2-[(2-[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl-2(3H)-benzothiazolone; adenosine 2a agonists, eg 2R,3R,4S,5R)-2-[6-Amino-2-(1 S-hydroxymethyl-2-phenyl-ethylamino)-purin-9-yl]-5-(2-ethyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol (e.g. as maleate); aa. integrin inhibitors eg (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl~oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy) acetyl]amino}pentanoyl)amino] propanoic acid (e.g as free acid or s potassium salt), diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium (eg as bromide), tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon; vaccines, diagnostics, and gene therapies. It will to be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.
is Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
Medicaments can also be delivered in combinations. Preferred formulations 2o containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) or formoterol (eg as the fumarate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate) or budesonide. A particularly preferred combination is a combination of 2s fluticasone propionate and salmeterol, or a salt thereof (particularly the xinafoate salt). A further combination of particular interest is budesonide and formoterol (e.g.
as the fumarate salt).
It may be appreciated that any of the parts of the medicament container used 3o therewith which contact the medicament may be coated with materials such as fluoropolymer materials which reduce the tendency of medicament to adhere thereto. Suitable fluoropolymers include polytetrafluoroethylene (PTFE) and fluoroethylene propylene (FEP). Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.
1o The application of which this description and claims form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described therein. They may take the form of product, method or use claims and may include, by way of example and without limitation, one or more of the following ~s claims:
Claims (51)
1. A container for a medicament powder formed from a material comprising a desiccant.
2. A container according to claim 1, wherein said container is an medicament dispenser comprising a body defining a reservoir for medicament in powder form, and an outlet in communication with said reservoir for release of medicament therefrom.
3. A container according to claim 1, wherein the container is an medicament dispenser comprising a body defining a chamber for receipt of a medicament carrier, and an outlet in communication with said chamber for release of medicament therefrom.
4. A container according to either of claims 2 or 3, wherein said body consists of said material comprising said desiccant.
5. A container according to either of claims 2 or 3, wherein said body comprises said material comprising said desiccant.
6. A container according to either of claims 2 or 3, wherein the material comprising the desiccant coats the body.
7. A container according to either of claims 2 or 3, wherein the material comprising the desiccant is impregnated throughout the body.
8. A container according to either of claims 2 or 3, wherein the material comprising the desiccant lines the body.
25~
25~
9. ~A container according to claim 1, wherein the container is a medicament carver.
10. ~A container according to claim 9 or 3, wherein said medicament carrier is a capsule comprising a wall enclosing the medicament.
11. ~A container according to claim 9 or 3, wherein the medicament carrier is a blister pack comprising a base sheet and a lid.
12. ~A container according to any of claims 9 to 11, wherein the medicament carrier comprises a material comprising a desiccant.
13. ~A container according to any of claims 9 to 11, wherein the material comprising the desiccant coats said wall, or said base sheet, or said lid of the medicament carrier.
14. ~A container according to any of claims 9 to 11, wherein the material comprising the desiccant impregnates the wall, or base sheet, or lid of the medicament carrier.
15. ~A container according to any of claims 9 to 11, wherein the material comprising the desiccant lines the wall, or base sheet, or lid of the medicament carrier.
16. ~A container according to any of claims 11 to 15, wherein a well containing desiccant surrounds individual pockets in said blister packs.
17. ~A container according to any of claims 11 to 16, wherein the blister pack comprises a laminate comprising a desiccant.
18. A container according to any of the preceding claims, wherein the material comprising the desiccant is an organic polymeric plastic.
19. A container according to claim 18, wherein said organic polymeric plastic is a polyamide.
20. A container according to any of the preceding claims, wherein the desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve and any mixtures thereof.
21. A container according to any of claims 1 to 20 additionally comprising a medicament in dry powder form.
22. A container according to claim 21, wherein said medicament is suitable for the treatment of respiratory disorders.
23. A container according to either of claims 21 or 22, wherein said medicament is salmeterol xinafoate.
24. A container according to either of claims 21 or 22, wherein said medicament is fluticasone propionate.
25. A container according to either of claims 21 or 22, wherein said medicament is a combination of salmeterol xinafoate and fluticasone propionate.
26. A method of reducing water ingress into a medicament powder comprising using a container for a medicament powder according to any of the preceding claims.
27. ~A package for storage of a container for a medicament powder formed from a material capable of controlling the ingress of moisture thereto or egress of moisture therefrom.
28. ~A package according to claim 27, wherein the material is capable of controlling the ingress or egress of moisture such that the moisture content within the package is essentially constant.
29. ~A package according to either of claims 27 or 28, wherein the material enables moisture transfer in one way only.
30. ~A package according to any of claims 27 to 29, wherein the material enables moisture transfer to a set maximum or minimum level within the package.
31. ~A package according to any of claims 27 to 29, wherein the material enables moisture transfer within a set maximum or minimum transfer rate.
32. ~A package according to any of claims 27 to 31, wherein said package is wrappable and sealable around the container to form an enclosed volume in which the container is disposed, thereby controlling ingress or egress of moisture.
33. ~A package according to claim 32, additionally comprising a desiccant within the enclosed volume.
34. ~A package according to claim 33, wherein said desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve and any mixtures thereof.
35. ~A package according to any of claims 27 to 34 wherein the package includes at least one heat sealable layer and at least one layer of a metal foil.
36. ~A package according to claim 35, wherein the metal comprising said metal foil is selected from the group consisting of aluminium, tin, iron, zinc and magnesium.
37. ~A package according to claim 36, wherein the package includes protective layers located on the outside of the package.
38. ~A package according to claim 37, wherein said protective layer comprises a polyester film and said heat sealable layer comprises an ionomer film.
39. ~A method of storing a container for a medicament powder comprising providing a packaging material which is capable of controlling the flow of water vapour;
filling a container with a medicament powder;
wrapping said container with said package material to form an enclosed volume in which said container is disposed therein; and sealing the package.
filling a container with a medicament powder;
wrapping said container with said package material to form an enclosed volume in which said container is disposed therein; and sealing the package.
40. ~A method of storing a container for a medicament powder according to claim 39, additionally comprising providing a desiccant within the enclosed volume.
41. ~A method according to either of claims 39 or 40, wherein said sealing comprises sealing said packaging material using a method selected from the group consisting of heat sealing, ultrasonic welding, laser welding, adhesive sealing and heat stamping.
42. ~A packaged container, comprising a container containing a medicament powder; and an overwrap package enclosing said container and a desiccant;
wherein said container and said desiccant are sealable within said overwrap.
wherein said container and said desiccant are sealable within said overwrap.
43. A packaged container according to claim 42, wherein said container is formed from a material comprising a desiccant.
44. A packaged powder medicament dispenser comprising a medicament dispenser for a medicament powder; and an overwrap package enclosing said medicament dispenser and a desiccant, wherein said medicament dispenser and said desiccant are sealable within said overwrap.
45. A packaged powder medicament dispenser comprising an medicament dispenser for a medicament powder; and an overwrap package enclosing said medicament dispenser, wherein said overwrap comprises desiccant.
46. A packaged powder medicament dispenser according to either of claims 44 or 45, wherein said desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water-absorbing clay, molecular sieve, zinc chloride and any mixtures thereof.
47. A container for a medicament powder formed from a material capable of controlling the ingress of moisture thereto or egress of moisture therefrom.
48. A container according to claim 47, wherein the material is capable of controlling the ingress or egress of moisture such that the moisture content within the package is essentially constant.
49. A container according to either of claims 47 or 48, wherein the material enables moisture transfer in one way only.
50. A container according to any of claims 47 to 49, wherein the material enables moisture transfer to a set maximum or minimum level within the package.
51. A container according to any of claims 47 to 49, wherein the material enables moisture transfer within a set maximum or minimum transfer rate.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0015043.3 | 2000-06-21 | ||
GBGB0015043.3A GB0015043D0 (en) | 2000-06-21 | 2000-06-21 | Medicament dispenser |
PCT/EP2001/006303 WO2001098174A1 (en) | 2000-06-21 | 2001-06-05 | Container for medicament powder |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2411109A1 true CA2411109A1 (en) | 2001-12-27 |
Family
ID=9894007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002411109A Abandoned CA2411109A1 (en) | 2000-06-21 | 2001-06-05 | Container for medicament powder |
Country Status (14)
Country | Link |
---|---|
US (2) | US7828150B2 (en) |
EP (2) | EP1292510B2 (en) |
JP (1) | JP2003535782A (en) |
CN (1) | CN1437551A (en) |
AT (1) | ATE353834T1 (en) |
AU (1) | AU2001274086A1 (en) |
BR (1) | BR0111252A (en) |
CA (1) | CA2411109A1 (en) |
DE (1) | DE60126609T3 (en) |
ES (1) | ES2282261T3 (en) |
GB (1) | GB0015043D0 (en) |
MX (1) | MXPA02012680A (en) |
WO (1) | WO2001098174A1 (en) |
ZA (1) | ZA200208212B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7954492B2 (en) | 2002-01-24 | 2011-06-07 | Almirall, S.A. | Pharmaceutical powder cartridge, and inhaler equipped with same |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US7171965B2 (en) * | 2000-02-01 | 2007-02-06 | Valois S.A.S. | Breath actuated dry powder inhaler and tape dose strip |
EP1241110A1 (en) * | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dispensing unit for oxygen-sensitive drugs |
SE0101825D0 (en) * | 2001-05-22 | 2001-05-22 | Astrazeneca Ab | An inhalation device |
DE60227833D1 (en) * | 2001-11-17 | 2008-09-04 | Aventis Pharma Ltd | PHARMACEUTICAL PRODUCT AND METHOD WITH ADSORBER |
GB0130857D0 (en) * | 2001-12-22 | 2002-02-06 | Glaxo Group Ltd | Medicament dispenser |
EP1894591B1 (en) | 2002-03-20 | 2013-06-26 | MannKind Corporation | Cartridge for an inhalation apparatus |
US20030235538A1 (en) * | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
CA2483914A1 (en) * | 2002-05-07 | 2003-11-20 | Nektar Therapeutics | Capsules for dry powder inhalers and methods of making and using same |
US7025205B2 (en) * | 2002-06-26 | 2006-04-11 | Aventis Pharma Limited | Method and packaging for pressurized containers |
GB0225621D0 (en) | 2002-11-02 | 2002-12-11 | Glaxo Group Ltd | Medicament carrier |
AU2003293833B2 (en) | 2002-12-12 | 2009-10-01 | Covis Pharma B.V. | Combination medicament |
US8377029B2 (en) * | 2003-04-23 | 2013-02-19 | Otsuka Pharmaceutical Factory, Inc. | Drug solution filling plastic ampoule and process for producing the same |
GB0312148D0 (en) | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
GB0315889D0 (en) | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
JP5618452B2 (en) | 2003-09-16 | 2014-11-05 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツングTakeda GmbH | Use of ciclesonide for the treatment of respiratory diseases |
SE0303569L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | DPI for delivery of moisture-sensitive drugs |
SE0303269L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medical product |
SE0303270L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Method of administration of tiotropium |
SE0303571D0 (en) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive drugs |
SE0303570L (en) | 2003-12-03 | 2005-06-04 | Microdrug Ag | Moisture-sensitive medical product |
FR2864944B1 (en) * | 2004-01-14 | 2006-03-31 | Valois Sas | STRIP OF BLISTERS FOR INHALER. |
SE530006C2 (en) * | 2004-06-18 | 2008-02-05 | Mederio Ag | Inhaler using tub |
SE0401654D0 (en) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | A support structure for a drug |
CN101010305B (en) | 2004-08-20 | 2010-08-11 | 曼金德公司 | Catalysis of diketopiperazine synthesis |
PL2322180T3 (en) | 2004-08-23 | 2015-10-30 | Mannkind Corp | Diketopiperazine salts for drug delivery |
MX2007004768A (en) * | 2004-10-21 | 2007-05-10 | Boehringer Ingelheim Int | Blister for inhalers. |
FR2877925B1 (en) * | 2004-11-16 | 2008-09-19 | Valois Sas | DEVICE FOR DISPENSING FLUID PRODUCT. |
GB0426780D0 (en) * | 2004-12-07 | 2005-01-12 | 3M Innovative Properties Co | Pressurized inhalation devices |
FR2881119B1 (en) * | 2005-01-25 | 2010-07-30 | Valois Sas | DEVICE FOR DISPENSING FLUID PRODUCT. |
CN100431634C (en) * | 2005-04-04 | 2008-11-12 | 陈庆堂 | Dry powder aerosolizing inhalator |
GB2425115A (en) * | 2005-04-15 | 2006-10-18 | Vectura Group Plc | Blister pack |
JP4659523B2 (en) * | 2005-04-26 | 2011-03-30 | 共同印刷株式会社 | Blister film and blister packaging container |
TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
CN104324362B (en) | 2005-09-14 | 2018-04-24 | 曼金德公司 | Method for preparation of drug based on improving affinity of the active agent to crystalline microparticle surfaces |
US20070114237A1 (en) * | 2005-11-23 | 2007-05-24 | Canegallo Pirottavio | System and method to dispense single capsular bodies |
EP1986722B1 (en) * | 2006-01-31 | 2018-10-24 | Oriel Therapeutics, Inc. | Dry powder inhalers having spiral travel paths for microcartridges with dry powder |
CN104383546B (en) | 2006-02-22 | 2021-03-02 | 曼金德公司 | Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent |
EP2141075B1 (en) * | 2007-04-27 | 2012-10-31 | Daiwa Can Company | Polyester resin container with fracturable portion and its production method |
EP2020249A1 (en) * | 2007-08-01 | 2009-02-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Inhalator |
US8881332B2 (en) * | 2007-08-17 | 2014-11-11 | Lise W. Noble | Toothbrush system utilizing oral care capsule |
WO2011163272A1 (en) | 2010-06-21 | 2011-12-29 | Mannkind Corporation | Dry powder drug delivery system and methods |
GB0800459D0 (en) * | 2008-01-11 | 2008-02-20 | Innovata Biomed Ltd | Improvements in or relating to inhalers |
HUE027246T2 (en) | 2008-01-24 | 2016-10-28 | Vectura Delivery Devices Ltd | Inhaler |
JP2011512209A (en) * | 2008-02-20 | 2011-04-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Powder inhaler |
PL2098249T3 (en) * | 2008-03-05 | 2013-03-29 | Rivopharm Sa | Nicorandil carriers with enhanced stability |
US20090235929A1 (en) * | 2008-03-19 | 2009-09-24 | Marc Egen | Powder inhalers |
DE102008018629A1 (en) * | 2008-04-11 | 2009-10-15 | Alcan Technology & Management Ag | Packaging film section, packaging film, packaging and packaging product unit |
IL191190A0 (en) * | 2008-05-01 | 2009-08-03 | Dan Adler | Dry powder inhaler |
US20090295108A1 (en) * | 2008-05-22 | 2009-12-03 | Albert Hisayuki Oku | Mobile Ball Hopper and Sport Bag Carrier |
DK2293833T3 (en) | 2008-06-13 | 2016-05-23 | Mannkind Corp | DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
KR101628410B1 (en) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | An interactive apparatus and method for real-time profiling of inhalation efforts |
EP2145758B2 (en) † | 2008-07-14 | 2017-06-07 | 3A Technology & Management AG | Packaging and packaging unit |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
US8919341B2 (en) * | 2008-12-03 | 2014-12-30 | Boehringer Ingelheim International Gmbh | Inhaler |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
KR100896958B1 (en) | 2009-02-12 | 2009-05-12 | 주식회사 제알코 | Packaging structure of medical supplies and packing method thereof |
JP5809985B2 (en) | 2009-02-26 | 2015-11-11 | グラクソ グループ リミテッドGlaxo Group Limited | A medicament comprising 4-{(1R) -2-[(6- {2-[(2,6-dichlorobenzyl) oxy] ethoxy} hexyl) amino] -1-hydroxyethyl} -2- (hydroxymethyl) phenol Formulation |
DK2405963T3 (en) | 2009-03-11 | 2013-12-16 | Mannkind Corp | DEVICE, SYSTEM AND PROCEDURE FOR MEASURING RESISTANCE IN AN INHALATOR |
BRPI1013154B1 (en) | 2009-06-12 | 2020-04-07 | Mannkind Corp | MICROPARTICLES OF DICETOPIPERAZINE WITH SPECIFIC SURFACE AREAS DEFINED, DRY POWDER UNDERSTANDING THE REFERRED MICROPARTICLES, METHOD FOR FORMATION OF THE REFERENCESMICROPARTICLES AND THE FORMATION OF MICROPARTYSTEMS |
CN102470209A (en) * | 2009-07-14 | 2012-05-23 | 赛诺菲-安万特德国有限公司 | Medicament container with a flexible inner layer and a rigid outer layer |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
TR200908847A2 (en) | 2009-11-23 | 2011-06-21 | Bi̇lgi̇ç Mahmut | Blister packaging carrying medicines in dry powder form. |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
JP5792307B2 (en) * | 2010-08-31 | 2015-10-07 | グラクソ グループ リミテッドGlaxo Group Limited | Dry powder inhalation drug product exhibiting moisture control characteristics and method of administration thereof |
EP2611423B2 (en) | 2010-08-31 | 2022-09-21 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
US20130153459A1 (en) * | 2010-09-01 | 2013-06-20 | Kyodo Printing Co., Ltd. | Package |
US8785183B2 (en) * | 2010-09-21 | 2014-07-22 | Biogaia Ab | Active plastic material in oil |
US9101305B2 (en) * | 2011-03-09 | 2015-08-11 | Medtronic Minimed, Inc. | Glucose sensor product and related manufacturing and packaging methods |
SG194034A1 (en) * | 2011-04-01 | 2013-11-29 | Mannkind Corp | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
PL3527197T3 (en) | 2012-01-25 | 2022-11-21 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation |
US8919559B2 (en) | 2012-03-28 | 2014-12-30 | Aventisub Ii Inc. | Package with break-away clamshell |
USD697813S1 (en) | 2012-03-28 | 2014-01-21 | Aventisub Ii Inc. | Clamshell having blisters received therein |
USD693695S1 (en) | 2012-03-28 | 2013-11-19 | Aventisub Ii Inc. | Package for product |
USD694644S1 (en) | 2012-03-28 | 2013-12-03 | Aventisub Ii Inc. | Clamshell package having blisters |
USD687313S1 (en) | 2012-03-28 | 2013-08-06 | Aventisub Ii Inc. | A-shaped blister card |
USD695625S1 (en) | 2012-03-28 | 2013-12-17 | Aventisub Ii Inc. | Package for product |
US8899419B2 (en) | 2012-03-28 | 2014-12-02 | Aventisub Ii Inc. | Package with break-away clamshell |
WO2013176635A1 (en) | 2012-05-25 | 2013-11-28 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhaler device having an improved guide gear |
CN108057154B (en) | 2012-07-12 | 2021-04-16 | 曼金德公司 | Dry powder drug delivery system and method |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
ES2928365T3 (en) | 2013-03-15 | 2022-11-17 | Mannkind Corp | Microcrystalline diketopiperazine compositions, methods of preparation and use thereof |
DK3409270T3 (en) | 2013-07-11 | 2021-04-26 | Chiesi Farm Spa | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
EP3021834A1 (en) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
CN105517607A (en) | 2013-08-05 | 2016-04-20 | 曼金德公司 | Insufflation apparatus and methods |
AU2015208875B2 (en) | 2014-01-23 | 2019-04-18 | Stasis Lmps Limited | Flexible panel and sealable bag with sorbent |
KR101964506B1 (en) * | 2014-03-27 | 2019-04-01 | 아반토 퍼포먼스 머티리얼즈, 엘엘씨 | Package system and method for inhibiting moisture entry |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9554992B2 (en) | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
KR101481733B1 (en) * | 2014-06-30 | 2015-01-12 | 주식회사 선양 | Dehumidifying and deodorizing functional compound having a three-layer packaging film and its manufacturing method |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
SI3377108T1 (en) | 2015-11-16 | 2020-05-29 | Chiesi Farmaceutici S.P.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
PL3377109T3 (en) | 2015-11-16 | 2020-09-21 | Chiesi Farmaceutici S.P.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
RU2734847C2 (en) * | 2016-07-07 | 2020-10-23 | Филип Моррис Продактс С.А. | Inhalation system for nicotine |
CN108622469B (en) * | 2017-03-24 | 2023-08-15 | 李和伟 | Crawler-type ware of dosing of independent packing |
US10350164B2 (en) | 2017-05-11 | 2019-07-16 | Chiesi Farmaceutici S.P.A. | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
BR112019023378A2 (en) | 2017-05-11 | 2020-06-16 | Chiesi Farmaceutici S.P.A. | PROCESS FOR PREPARING A POWDER FORMULATION FOR INHALATION FOR USE IN A DRY POWDER INHALER |
GB201710653D0 (en) | 2017-07-03 | 2017-08-16 | One Hundred Flowers Ltd | Inhaler |
US20190076607A1 (en) * | 2017-09-13 | 2019-03-14 | Lupin Atlantis Holdings Sa | Inhaler and mesh for an inhaler |
US11896720B2 (en) * | 2017-09-26 | 2024-02-13 | Captek Softgel International | Orally available articles containing at least one stabilized supplement therein |
CL2017002724A1 (en) * | 2017-10-26 | 2018-07-13 | Univ Adolfo Ibanez | Device that allows humidity levels to be controlled inside a container |
US20210316087A1 (en) * | 2018-06-29 | 2021-10-14 | Csp Technologies, Inc. | Low odor or no odor inhaler desiccant polymer |
CN110338465A (en) * | 2019-07-16 | 2019-10-18 | 深圳麦克韦尔科技有限公司 | Scavenging air valve and electronic atomization device |
WO2023117967A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US577532A (en) * | 1897-02-23 | Annunciator | ||
US2524162A (en) | 1945-02-27 | 1950-10-03 | Chavannes Marc Alfred | Desiccant packaging |
US2517482A (en) * | 1949-04-09 | 1950-08-01 | Sharp & Dohme Inc | Inhaler |
FR1398104A (en) * | 1964-03-26 | 1965-05-07 | Participations Et Procedes Ind | desiccant elements and their manufacturing process |
CH434104A (en) | 1964-05-01 | 1967-04-15 | Schuepbach Ag | Conditioning packaging material |
US3333683A (en) | 1966-02-17 | 1967-08-01 | Anaconda Aluminum Co | Cigarette package |
US3371825A (en) | 1966-05-12 | 1968-03-05 | Multiform Desiccant Products I | Sorptive getter for pressure discharge dispensers |
NL6900448A (en) | 1968-12-05 | 1970-06-09 | ||
FR2086553A5 (en) | 1970-04-01 | 1971-12-31 | Oreal | |
US3704806A (en) | 1971-01-06 | 1972-12-05 | Le T Im Lensoveta | Dehumidifying composition and a method for preparing the same |
US3809223A (en) | 1971-08-27 | 1974-05-07 | Crown Zellerbach Corp | Protected lumber package and method of making same |
US3921805A (en) * | 1972-10-10 | 1975-11-25 | Newton L Compere | Rupturable blister pill package with safety backing |
US3788322A (en) | 1972-12-27 | 1974-01-29 | Alza Corp | Drug delivery device with means for maintaining device in environment of use |
US3797492A (en) | 1972-12-27 | 1974-03-19 | Alza Corp | Device for dispensing product with directional guidance member |
US4135622A (en) | 1973-03-28 | 1979-01-23 | American Cyanamid Company | Packaged, desiccated surgical elements |
SE382606B (en) | 1975-05-06 | 1976-02-09 | Svenska Dental Instrument Ab | STERILE PACKAGING |
CA1097233A (en) * | 1977-07-20 | 1981-03-10 | George K. E. Gregory | Packages |
US4274403A (en) * | 1979-08-29 | 1981-06-23 | Struve Roger L | Inhaler |
DE3110947A1 (en) * | 1981-03-20 | 1982-10-07 | Dieter Gräßlin Feinwerktechnik, 7742 St Georgen | "PROGRAM INPUT AND / OR TIME SETTING DEVICE" |
US4702963A (en) | 1981-04-03 | 1987-10-27 | Optical Coating Laboratory, Inc. | Flexible polymer film with vapor impermeable coating |
US4429792A (en) * | 1981-09-11 | 1984-02-07 | Medication Services, Inc. | Medication-dispensing card |
US4447565A (en) | 1981-12-07 | 1984-05-08 | The United States Of America As Represented By The United States Department Of Energy | Method and composition for molding low density desiccant syntactic foam articles |
US4363841A (en) | 1981-12-28 | 1982-12-14 | Champion International Corporation | Laminated packaging material |
US4447585A (en) * | 1982-03-04 | 1984-05-08 | The Goodyear Tire & Rubber Company | Polymer bound aryl substituted crown ethers |
US4449632A (en) | 1982-12-15 | 1984-05-22 | Marusiak Jr Frank | Tamper-proof package and method |
US4570820A (en) | 1983-01-18 | 1986-02-18 | Creative Products Resource Associates, Ltd. | Resealable dispensing container for folded towels |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4509196A (en) | 1983-06-30 | 1985-04-02 | Arvey Corporation | Tamper-indicating self-sealing pouch |
US4664256A (en) | 1983-09-06 | 1987-05-12 | Farmaceutisk Laboratorium Ferring A/S | Packaged stable enema solution or suspension containing 5-aminosalicyclic acid |
US4655229A (en) | 1984-01-30 | 1987-04-07 | R. J. Reynolds Tobacco Company | Flavor delivery system |
US6022627A (en) | 1993-08-17 | 2000-02-08 | Southpac Trust International, Inc. | Floral wrapper utilizing a breathable packaging material |
US5743398A (en) | 1984-05-22 | 1998-04-28 | Southpac Trust International, Inc. | Floral wrapper utilizing a breathable packaging material |
SE465417B (en) | 1984-06-21 | 1991-09-09 | Toyo Seikan Kaisha Ltd | PLASTIC CONTAINERS MADE OF LAMINATE INCLUDING A GAS BARRIER LAYER |
US4665229A (en) * | 1985-02-14 | 1987-05-12 | Ashland Oil, Inc. | Preparation of hydroxy alkyl amide thio ether compounds from bicyclic amide acetal and thiol |
US4645073A (en) | 1985-04-02 | 1987-02-24 | Survival Technology, Inc. | Anti-contamination hazardous material package |
DE3524846A1 (en) | 1985-07-12 | 1987-01-15 | Hoechst Ag | PACKING FOR DRY RESISTANT MATERIAL |
US4938238A (en) | 1985-08-26 | 1990-07-03 | R. J. Reynolds Tobacco Company | Smoking article with improved wrapper |
US5073599A (en) | 1985-11-29 | 1991-12-17 | American National Can Company | Films using blends of polypropylene and polyisobutylene |
DE8605885U1 (en) † | 1986-03-04 | 1986-04-17 | Eurim-Pharm Arzneimittel GmbH, 8235 Piding | Child lock for blister strips |
DE3610345C2 (en) | 1986-03-27 | 1998-07-09 | Rathor Ag | Device for producing polyurethane assembly foam |
US4720423A (en) | 1986-08-25 | 1988-01-19 | Minnesota Mining And Manufacturing Company | Package opening system |
US4757919A (en) | 1986-09-23 | 1988-07-19 | The Coca-Cola Company | Shut-off valve for juice dispensing system |
US4718553A (en) | 1987-02-11 | 1988-01-12 | Ivy Hill Corporation | Tamper-evident packaging, method of making same, and intermediate therein |
DE3715938A1 (en) | 1987-05-13 | 1988-11-24 | Boehringer Mannheim Gmbh | CONTAINER FOR TEST STRIP |
CA1329526C (en) | 1987-08-20 | 1994-05-17 | Hiroshi Ikura | Powdery medicine applicator device |
US4815602A (en) | 1987-10-30 | 1989-03-28 | W.R. Grace & Co. | Vacuum skin package for closing two moisture impervious metallic sheets about a product |
US4802583A (en) | 1988-03-11 | 1989-02-07 | The Mead Corporation | Article container with overwrap |
US4811571A (en) | 1988-03-28 | 1989-03-14 | Thermo King Corporation | Refrigerant drier |
US4861632A (en) | 1988-04-19 | 1989-08-29 | Caggiano Michael A | Laminated bag |
US4907394A (en) | 1988-05-27 | 1990-03-13 | Unionpack Industrielle Lohnverpackuns-Gmbh & Co. | Method for producing a foil-container, apparatus for the implementation of the said method, and a foil-container produced according to the said method |
JP2592500B2 (en) | 1988-06-01 | 1997-03-19 | 三井石油化学工業株式会社 | Laminated film |
US5062569A (en) | 1988-08-01 | 1991-11-05 | Hekal Ihal M | Peelably sealed plastic packages and method of preparing same |
US4934524A (en) | 1988-09-19 | 1990-06-19 | Brown & Williamson Tobacco Corporation | Package for storing moisture laden articles |
US5186775A (en) | 1988-10-05 | 1993-02-16 | Cullen John S | Method of fabrication of a container for bulk material |
US4874090A (en) | 1988-10-24 | 1989-10-17 | American Sterilizer Company | Self-seal sterilization pouch |
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5035935A (en) | 1989-01-19 | 1991-07-30 | Philip Morris Incorporated | Overwrap insert |
US5718355A (en) | 1989-02-03 | 1998-02-17 | Senetics, Inc. | Indicator device responsive to axial force for use with inhaler |
GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
US4972953A (en) | 1989-06-14 | 1990-11-27 | Ivy Hill Corporation | Tamper-evident packaging, method of making same and intermediate therein |
GB8919131D0 (en) | 1989-08-23 | 1989-10-04 | Riker Laboratories Inc | Inhaler |
US5270305A (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
GB8925707D0 (en) | 1989-11-14 | 1990-01-04 | Riker Laboratories Inc | Device |
US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
US5113855A (en) | 1990-02-14 | 1992-05-19 | Newhouse Michael T | Powder inhaler |
US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
US5814337A (en) * | 1992-10-07 | 1998-09-29 | Beecham Group Plc | Pharmaceutical formulation |
DE4013799A1 (en) | 1990-04-28 | 1991-10-31 | Gaplast Gmbh | PLASTIC CONTAINER AND CONTAINER CLOSURE, ESPECIALLY FOR MEDICINAL PRODUCTS |
US5192548A (en) * | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
US5126123A (en) | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
US5304419A (en) | 1990-07-06 | 1994-04-19 | Alpha Fry Ltd | Moisture and particle getter for enclosures |
DE4027391A1 (en) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | GAS-FREE INHALATION DEVICE |
US5042472A (en) * | 1990-10-15 | 1991-08-27 | Merck & Co., Inc. | Powder inhaler device |
AU662919B2 (en) | 1991-07-02 | 1995-09-21 | Inhale, Inc. | Method and device for delivering aerosolized medicaments |
US6119688A (en) | 1991-08-26 | 2000-09-19 | 3M Innovative Properties Company | Powder dispenser |
US5916540A (en) | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
GB9203761D0 (en) * | 1992-02-21 | 1992-04-08 | Innovata Biomed Ltd | Inhaler |
US5330047A (en) | 1992-04-27 | 1994-07-19 | Rhone-Poulenc Inc. | Packaging for agrichemicals |
US5394868A (en) | 1992-06-25 | 1995-03-07 | Schering Corporation | Inhalation device for powdered medicaments |
CA2099940A1 (en) | 1992-07-06 | 1994-01-07 | Kenneth A. Thomas | Tear tape |
ATE153299T1 (en) * | 1992-09-09 | 1997-06-15 | Fisons Plc | PHARMACEUTICAL PACKAGING |
GB2272162B (en) | 1992-11-06 | 1996-10-09 | Paul Richard Yerbury | Dust proof inhaler |
US5322161A (en) | 1992-11-30 | 1994-06-21 | United States Surgical Corporation | Clear package for bioabsorbable articles |
RU2111020C1 (en) | 1992-12-18 | 1998-05-20 | Шеринг Корпорейшн | Powdered drug inhaler |
US5756171A (en) | 1992-12-22 | 1998-05-26 | Kabushiki Kaisha Hosokawa Yoko | Laminate film and method of producing the same |
US5441060A (en) | 1993-02-08 | 1995-08-15 | Duke University | Dry powder delivery system |
GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
AU695969B2 (en) | 1993-04-30 | 1998-08-27 | Minnesota Mining And Manufacturing Company | Seal configuration for aerosol canister |
JPH0796977A (en) | 1993-06-08 | 1995-04-11 | Ajinomoto Co Inc | Double packing material for easily oxidized substance |
US5451437A (en) | 1993-06-21 | 1995-09-19 | Minnesota Mining And Manufacturing Company | Method and article for protecting a container that holds a fluid |
JPH0733172A (en) * | 1993-07-08 | 1995-02-03 | Toppan Printing Co Ltd | Multi-layer plastic container |
US5524613A (en) | 1993-08-25 | 1996-06-11 | Habley Medical Technology Corporation | Controlled multi-pharmaceutical inhaler |
GB9404945D0 (en) * | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
GB9405249D0 (en) * | 1994-03-17 | 1994-04-27 | Smithkline Beecham Plc | Container |
US5472092A (en) | 1994-03-30 | 1995-12-05 | H. J. Heinz Company | Shrink wrapped package and method for its production |
GB9411626D0 (en) | 1994-06-10 | 1994-08-03 | Smithkline Beecham Plc | Package |
TW272163B (en) | 1994-06-24 | 1996-03-11 | Mitsubishi Gas Chemical Co | |
BR9508935A (en) | 1994-09-16 | 1998-01-06 | Laboraire Glaxo Wellcome S A | Inhalation device |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5551557A (en) | 1994-10-25 | 1996-09-03 | Convey, Inc. | Efficient method and apparatus for establishing shelf-life of getters utilized within sealed enclosures |
US5565164A (en) * | 1995-03-17 | 1996-10-15 | Limited Resources, Inc. | Method and apparatus for densifying a thermoplastic polymer |
RO119117B1 (en) | 1995-04-14 | 2004-04-30 | Glaxo Wellcome Inc. | Fixed dose inhaler for fluticasone propionate |
WO1996032099A1 (en) | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for albuterol |
US6279736B1 (en) * | 1995-04-19 | 2001-08-28 | Capitol Specialty Plastics, Inc. | Barrier pack having an absorbing agent applied to the interior of the pack |
AU5550196A (en) * | 1995-04-19 | 1996-11-07 | Capitol Vial, Inc. | Desiccant material included in a closed container |
US5911937A (en) | 1995-04-19 | 1999-06-15 | Capitol Specialty Plastics, Inc. | Desiccant entrained polymer |
US6194079B1 (en) † | 1995-04-19 | 2001-02-27 | Capitol Specialty Plastics, Inc. | Monolithic polymer composition having an absorbing material |
US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5622166A (en) * | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
GB2306169B (en) | 1995-10-13 | 2000-01-12 | Eastman Kodak Co | Zeolite molecular sieves for packaging structures |
US5789044A (en) | 1996-01-24 | 1998-08-04 | Eastman Kodak Company | Zeolite molecular sieves for packaging structures |
US5833066A (en) | 1996-01-02 | 1998-11-10 | Inhalermate, Llc | Carrying case for oral and nasal inhalation devices with counting mechanism |
IL125183A0 (en) | 1996-01-03 | 1999-03-12 | Glaxo Group Ltd | Inhalation device |
US5833093A (en) | 1996-03-04 | 1998-11-10 | Honaker; Denise | Protective cover for small spray dispensers and medicated inhalers |
US5773105A (en) | 1996-03-07 | 1998-06-30 | United Catalysts Inc. - Desiccants | Absorbent packet |
US5749496A (en) | 1996-06-19 | 1998-05-12 | Primary Delivery Systems, Inc. | Squeeze and rotate to lift captive cap dispenser |
US6112888A (en) † | 1996-06-28 | 2000-09-05 | W. R. Grace & Co.-Conn. | Non-reclosable packages containing desiccant matrix |
DE19633495A1 (en) | 1996-08-20 | 1998-02-26 | Sanner Friedr Gmbh Co Kg | Desiccant seal for container filled with moisture sensitive goods |
DE19646048C2 (en) | 1996-11-08 | 2003-05-28 | Michael Horstmann | Packaging for transdermal therapeutic systems |
SE9700944D0 (en) | 1997-03-14 | 1997-03-14 | Astra Ab | Powder inhales VI |
US5779122A (en) | 1997-05-05 | 1998-07-14 | Martinelli; Vincent | Asthma medication pouch |
US6093480A (en) | 1997-05-21 | 2000-07-25 | Tenneco Packaging | Stretch wrap films |
US6103280A (en) | 1997-09-20 | 2000-08-15 | Bass Public Limited Company | Self-cooling containers of beverage and foodstuffs |
US6617321B2 (en) * | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
SK9562000A3 (en) † | 1997-12-22 | 2000-11-07 | Astrazeneca Ab | A suction tube and inhalation device comprising such a tube |
US6039718A (en) | 1998-01-20 | 2000-03-21 | Bracco Research Usa | Multiple use universal connector |
US6019751A (en) | 1998-01-20 | 2000-02-01 | Bracco Research Usa | Universal connector and a medical container |
JPH11206850A (en) * | 1998-01-29 | 1999-08-03 | Dai Ichi Seiyaku Co Ltd | Drug packaging body |
US5896989A (en) | 1998-02-20 | 1999-04-27 | Bracco Research Usa | Flexible medical container packaging |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
US6207093B1 (en) | 1998-04-24 | 2001-03-27 | Fina Technology, Inc. | Compositions for improved orientation processing |
US6241132B1 (en) | 1998-05-13 | 2001-06-05 | The Testor Corporation | Fluid dispensing apparatus with fitment spout and valve |
CN1308574A (en) * | 1998-06-04 | 2001-08-15 | 卡皮托特种塑料公司 | Desiccant blended in a thermoplastic |
US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6250468B1 (en) | 1999-02-10 | 2001-06-26 | Teepak Investments, Inc. | Easy to remove overwrap |
US6531197B2 (en) | 1999-04-26 | 2003-03-11 | Illinois Tool Works | Desiccant barrier container |
FR2793379B1 (en) | 1999-05-11 | 2001-07-06 | Kuhn Sa | ADAPTER FOR A TRACTOR HITCH BAR |
US6360929B1 (en) | 2000-07-17 | 2002-03-26 | Mccarthy Madeleine | Medicinal atomizing inhaler pouch/retainer |
FR2812620B1 (en) * | 2000-08-04 | 2002-12-27 | David Platre | REVERSIBLE SEALING DEVICE FOR CONTAINER |
US20060269708A1 (en) | 2002-06-20 | 2006-11-30 | Rick Merical | Films having a desiccant material incorporated therein and methods of use and manufacture |
US20030235664A1 (en) | 2002-06-20 | 2003-12-25 | Rick Merical | Films having a desiccant material incorporated therein and methods of use and manufacture |
US20040131805A1 (en) | 2002-06-20 | 2004-07-08 | Merical Rick L. | Films having a desiccant material incorporated therein and methods of use and manufacture |
SE0401654D0 (en) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | A support structure for a drug |
MX2007004768A (en) | 2004-10-21 | 2007-05-10 | Boehringer Ingelheim Int | Blister for inhalers. |
-
2000
- 2000-06-21 GB GBGB0015043.3A patent/GB0015043D0/en not_active Ceased
-
2001
- 2001-06-05 DE DE60126609T patent/DE60126609T3/en not_active Expired - Lifetime
- 2001-06-05 WO PCT/EP2001/006303 patent/WO2001098174A1/en active IP Right Grant
- 2001-06-05 EP EP01940550A patent/EP1292510B2/en not_active Expired - Lifetime
- 2001-06-05 AT AT01940550T patent/ATE353834T1/en not_active IP Right Cessation
- 2001-06-05 CA CA002411109A patent/CA2411109A1/en not_active Abandoned
- 2001-06-05 EP EP06075817A patent/EP1760008A1/en not_active Withdrawn
- 2001-06-05 US US10/276,932 patent/US7828150B2/en not_active Expired - Lifetime
- 2001-06-05 MX MXPA02012680A patent/MXPA02012680A/en unknown
- 2001-06-05 JP JP2002503623A patent/JP2003535782A/en active Pending
- 2001-06-05 CN CN01811527A patent/CN1437551A/en active Pending
- 2001-06-05 AU AU2001274086A patent/AU2001274086A1/en not_active Abandoned
- 2001-06-05 BR BR0111252-0A patent/BR0111252A/en not_active IP Right Cessation
- 2001-06-05 ES ES01940550T patent/ES2282261T3/en not_active Expired - Lifetime
-
2002
- 2002-10-11 ZA ZA200208212A patent/ZA200208212B/en unknown
-
2006
- 2006-06-29 US US11/427,370 patent/US20060249419A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7954492B2 (en) | 2002-01-24 | 2011-06-07 | Almirall, S.A. | Pharmaceutical powder cartridge, and inhaler equipped with same |
Also Published As
Publication number | Publication date |
---|---|
ZA200208212B (en) | 2003-07-17 |
WO2001098174A1 (en) | 2001-12-27 |
US7828150B2 (en) | 2010-11-09 |
BR0111252A (en) | 2003-06-03 |
MXPA02012680A (en) | 2003-04-25 |
US20030140923A1 (en) | 2003-07-31 |
DE60126609T2 (en) | 2007-10-31 |
EP1760008A1 (en) | 2007-03-07 |
GB0015043D0 (en) | 2000-08-09 |
ATE353834T1 (en) | 2007-03-15 |
EP1292510A1 (en) | 2003-03-19 |
CN1437551A (en) | 2003-08-20 |
EP1292510B2 (en) | 2011-07-20 |
DE60126609T3 (en) | 2012-01-26 |
EP1292510B1 (en) | 2007-02-14 |
JP2003535782A (en) | 2003-12-02 |
US20060249419A1 (en) | 2006-11-09 |
ES2282261T3 (en) | 2007-10-16 |
AU2001274086A1 (en) | 2002-01-02 |
DE60126609D1 (en) | 2007-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7828150B2 (en) | Container for medicament powder | |
US20050039743A1 (en) | Medicament dispenser | |
US6119853A (en) | Method and package for storing a pressurized container containing a drug | |
US10376662B2 (en) | Dry powder inhalers | |
US6352152B1 (en) | Method and package for storing a pressurized container containing a drug | |
US6390291B1 (en) | Method and package for storing a pressurized container containing a drug | |
US20020048552A1 (en) | Method and package for storing a pressurized container containing a drug | |
US20060032763A1 (en) | Method and package for storing a pressurized container containing a drug | |
WO2001097888A2 (en) | Method and package for storing a pressurized container containing a drug | |
US20040089561A1 (en) | Method and package for storing a pressurized container containing a drug | |
MXPA01005898A (en) | Method and package for storing a pressurized container containing a drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |